≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Biological medicines for asthma

Endpoint Browser PheWeb

RX_ASTMA_BIOL

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Medicine purchases: ATC — R03DX05|R03DX08|R03DX09|R03DX10|D11AH05

1 out of 7 registries used, show all original rules.

892

4. Check minimum number of events

Min. number of events 3
892

5. Include endpoints

None

892

6. Filter based on genotype QC (FinnGen only)

860

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1297 753 538
Only index persons 1280 749 531
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.03 0.02
Median age at first event (years)
Whole population 50.20 49.28 51.58
Only index persons 50.32 49.31 51.75

-FinnGen-

Key figures

All Female Male
Number of individuals 860 545 315
Unadjusted period prevalence (%) 0.18 0.19 0.14
Median age at first event (years) 55.67 54.47 57.75

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
892
Matched controls
8920
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
16.7
311.2
305
269
R03AK08
ATC
formoterol and beclometasone; inhalant
18.4
309.4
282
219
J32.4
ICD-10 Finland
Chronic pansinusitis
60.0
307.7
222
49
J45.1
ICD-10 Finland
Nonallergic asthma
17.1
307.7
335
303
R03BB04
ATC
tiotropium bromide; inhalant
20.9
307.7
388
317
ZX112
NOMESCO Finland
Subcutaneous
50.7
307.7
225
59
J33.0
ICD-10 Finland
Polyp of nasal cavity
31.7
307.7
248
107
R03DC03
ATC
montelukast; oral
25.9
307.7
687
1022
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
29.8
307.7
242
110
J45.9
ICD-10 Finland
Asthma, unspecified
12.7
307.7
556
1029
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
17.5
307.7
621
1032
395
Kela drug reimbursment
Dupilumab
6855.0
307.7
406
*
J45.0
ICD-10 Finland
Predominantly allergic asthma
16.3
307.7
435
491
D11AH05
ATC
dupilumab; topical
7912.2
307.7
439
*
H02AB06
ATC
prednisolone; systemic
38.5
277.7
849
3025
J33.8
ICD-10 Finland
Other polyp of sinus
31.5
270.9
184
73
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
30.0
253.9
175
72
J46
ICD-10 Finland
Status asthmaticus
24.3
253.2
191
99
R03DX05
ATC
omalizumab; parenteral
+∞
249.0
227
*
344
Kela drug reimbursment
Omalizumab
+∞
242.0
221
*
D11AH01
ATC
tacrolimus; topical
49.1
238.9
141
34
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
14.1
235.2
245
233
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.7
231.2
313
430
DHB20
NOMESCO Finland
Polypectomy of internal nose
41.3
227.1
140
40
UDH02
NOMESCO Finland
Rhinopharyngoscopy
11.3
224.2
281
348
XG474
NOMESCO Finland
Exhalation nntrogen oxide
18.8
219.1
186
123
J45
ICD-10 Finland
Asthma
9.2
214.8
339
557
GX1L5
NOMESCO Finland
Exhaled nitric oxide analysis
42.5
209.7
128
35
XQ800
NOMESCO Finland
Prick test
9.8
202.2
286
410
R03DX09
ATC
mepolizumab; parenteral
+∞
199.7
184
*
L50.1
ICD-10 Finland
Idiopathic urticaria
52.7
192.0
111
24
3028
Kela drug reimbursment
Mepolizumab
2331.5
190.7
178
*
R06AX27
ATC
desloratadine; oral
7.3
183.2
624
2153
297, ,
Kela drug reimbursment
+∞
179.4
166
*
R03AK11
ATC
formoterol and fluticasone; inhalant
21.9
178.6
138
74
TDM10
NOMESCO Finland
Puncture of maxillary antrum
13.0
177.6
188
180
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
17.4
175.7
153
105
R03AK06
ATC
salmeterol and fluticasone; inhalant
7.4
175.2
339
681
R03DA04
ATC
theophylline; systemic, rectal
16.0
175.1
160
120
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
15.0
173.2
165
133
J45.8
ICD-10 Finland
Mixed asthma
16.9
173.0
153
108
L20.0
ICD-10 Finland
Besnier prurigo
8.2
172.7
287
490
R03BA08
ATC
ciclesonide; inhalant
8.1
168.3
279
474
R01AD08
ATC
fluticasone; nasal
6.4
167.1
569
1921
L50.8
ICD-10 Finland
Other urticaria
21.9
165.3
127
67
R96
ICPC
Asthma
8.1
160.8
264
442
R03BA02
ATC
budesonide; inhalant
6.3
160.7
402
1025
D11AH02
ATC
pimecrolimus; topical
52.6
155.9
90
19
C01CA24
ATC
epinephrine; parenteral
8.3
155.0
242
382
R06AE09
ATC
levocetirizine; oral
6.3
153.6
364
878
R03AC13
ATC
formoterol; inhalant
11.4
143.1
163
172
DPA25
NOMESCO Finland
Trephine of frontal sinus through nose
28.5
141.5
97
38
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
24.9
141.2
102
46
DPA30
NOMESCO Finland
Sphenotomy
36.5
136.1
86
26
L50.9
ICD-10 Finland
Urticaria, unspecified
10.2
133.6
165
194
L04AD01
ATC
ciclosporin; systemic
18.6
133.4
110
67
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
10.9
128.5
150
163
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.1
125.0
154
180
H02AB04
ATC
methylprednisolone; systemic
5.8
124.5
297
706
R03AK07
ATC
formoterol and budesonide; inhalant
5.0
124.2
425
1367
R03DX10
ATC
benralizumab; systemic
+∞
123.9
116
*
R03AC02
ATC
salbutamol; inhalant
8.3
123.4
781
4093
D11AX14
ATC
[U] tacrolimus
48.1
120.8
71
16
H02AB07
ATC
prednisone; oral
6.0
120.7
271
608
3027
Kela drug reimbursment
Benralizumab
+∞
120.6
113
*
R03BA05
ATC
fluticasone; inhalant
5.1
118.3
361
1053
J33.9
ICD-10 Finland
Nasal polyp, unspecified
22.6
117.6
88
43
R03AC12
ATC
salmeterol; inhalant
11.7
116.3
127
125
251, ,
Kela drug reimbursment
+∞
116.2
109
*
UDM02
NOMESCO Finland
Sinoscopy
13.8
116.0
113
93
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
10.9
110.7
127
134
R06AE07
ATC
cetirizine; oral
4.9
106.3
651
3151
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
5.7
105.4
239
536
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.5
104.7
148
204
R06AX22
ATC
ebastine; oral
4.6
101.5
340
1050
TQW80
NOMESCO Finland
Local dermatologic skincare
12.8
98.9
100
87
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
33.2
95.8
62
20
R01AD58
ATC
fluticasone, combinations; nasal
4.0
90.8
457
1864
D07AB08
ATC
desonide; topical
5.1
90.0
229
562
XQ802
NOMESCO Finland
Epicutan test
7.6
86.8
133
200
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.6
85.4
131
197
XG410
NOMESCO Finland
Flow-volume spirometry
9.3
84.8
108
130
49300
ICD-8 Finland
Asthma, bronchiale
13.2
84.2
83
69
D02AE01
ATC
carbamide; topical
6.6
82.3
146
256
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
5.7
81.9
175
367
R03BA01
ATC
beclometasone; inhalant
4.5
79.7
243
684
H02AB09
ATC
hydrocortisone; systemic
11.8
77.6
82
76
E0000UV, ,
ATC
3.6
76.7
557
2797
D07AC01
ATC
betamethasone; topical
3.5
75.6
489
2278
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
75.3
549
2753
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
11.2
74.9
82
80
L04AX03
ATC
methotrexate; systemic
4.8
73.7
199
507
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
4.3
73.6
240
707
D07BA04
ATC
hydrocortisone and antiseptics; topical
4.8
73.3
197
500
R03AC03
ATC
terbutaline; inhalant
4.2
72.7
246
744
WZC30
NOMESCO Finland
Teaching
4.0
72.0
265
851
Z88.6
ICD-10 Finland
Personal history of allergy to analgesic agent
260.7
71.4
72
*
R01AD12
ATC
fluticasone furoate; nasal
3.4
70.9
491
2360
D07AA02
ATC
hydrocortisone; topical
3.9
70.1
263
854
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.8
69.8
141
279
Z51.6
ICD-10 Finland
Desensitization to allergens
15.1
68.7
62
44
D02AX
ATC
Other emollients and protectives
9.1
67.9
87
105
R01AD05
ATC
budesonide; nasal
5.0
67.0
164
384
R01AD09
ATC
mometasone; nasal
3.5
66.8
611
3428
R06AX13
ATC
loratadine; oral
3.7
64.9
273
953
R06AX26
ATC
fexofenadine; oral
4.7
62.1
163
403
R03DC01
ATC
zafirlukast; oral
14.0
61.9
58
44
J32.2
ICD-10 Finland
Chronic ethmoidal sinusitis
22.0
61.5
46
22
D09AB01
ATC
zinc bandage without supplements; topical
13.4
60.3
58
46
J01MA14
ATC
moxifloxacin; systemic
4.7
58.5
152
372
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
13.9
58.4
55
42
L50.3
ICD-10 Finland
Dermatographic urticaria
9.7
57.9
70
78
E000003, ,
ATC
6.1
57.9
108
197
E000002, ,
ATC
4.0
56.8
195
588
ZXC95
NOMESCO Finland
Use of surgical navigator
14.0
56.6
53
40
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.7
56.4
225
751
R02
ICPC
Shortness of breath/dyspnoea
3.9
56.2
202
628
ZXA10
NOMESCO Finland
Bilateral
3.6
56.2
237
820
J33
ICD-10 Finland
Nasal polyp
17.1
55.9
47
29
E000001, ,
ATC
3.3
55.4
291
1153
D07AB02
ATC
hydrocortisone butyrate; topical
3.0
54.7
390
1837
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
5.6
54.7
111
219
D07AD01
ATC
clobetasol; topical
3.5
54.4
243
871
XQ848
NOMESCO Finland
Dermatological photography
8.1
54.2
76
102
D07AC13
ATC
mometasone; topical
3.0
53.5
370
1710
L50
ICD-10 Finland
Urticaria
9.0
53.4
68
81
S01GX01
ATC
cromoglicic acid; ophthalmic
3.1
52.6
317
1354
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.9
51.8
386
1851
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
8.0
51.1
72
97
L20
ICD-10 Finland
Atopic dermatitis
6.2
51.0
92
162
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.1
50.4
277
1119
N05BB01
ATC
hydroxyzine; systemic
4.9
50.2
121
277
L27.2
ICD-10 Finland
Dermatitis due to ingested food
14.3
48.8
45
33
J47
ICD-10 Finland
Bronchiectasis
12.3
48.4
49
42
J30.3
ICD-10 Finland
Other allergic rhinitis
5.6
48.2
98
193
J01FA06
ATC
roxithromycin; oral
2.7
47.5
460
2498
L28.1
ICD-10 Finland
Prurigo nodularis
17.7
47.3
39
23
ZX109
NOMESCO Finland
Instruction on medicine inhalation technique
16.3
45.4
39
25
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.2
45.1
133
356
WQ000
NOMESCO Finland
Hyposensibilisation
15.8
43.6
38
25
R01AD01
ATC
beclometasone; nasal
3.1
43.3
228
890
DHB50
NOMESCO Finland
Turbinoplasty
6.5
42.7
72
118
J01FA10
ATC
azithromycin; systemic
2.9
42.6
671
4547
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.7
41.9
607
3927
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
3.5
41.6
167
552
J01AA02
ATC
doxycycline; systemic
3.6
41.5
770
5668
J31.0
ICD-10 Finland
Chronic rhinitis
3.6
40.4
156
502
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
40.2
262
1144
J32.9
ICD-10 Finland
Chronic sinusitis, unspecified
10.5
40.1
45
45
S87
ICPC
Dermatitis/atopic eczema
6.6
39.5
66
107
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.6
39.2
101
243
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.6
38.8
327
1621
R06.0
ICD-10 Finland
Dyspnoea
2.7
38.5
301
1437
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
9.3
38.4
47
53
J01FA09
ATC
clarithromycin; systemic
2.4
36.2
382
2089
T78.4
ICD-10 Finland
Allergy, unspecified
4.5
35.1
92
224
H65.3
ICD-10 Finland
Chronic mucoid otitis media
6.2
34.7
61
104
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.4
34.5
415
2391
R01AD11
ATC
triamcinolone; nasal
3.4
34.3
137
448
134
Kela drug reimbursment
General erythroderma
43.9
34.3
42
10
R01BA52
ATC
pseudoephedrine, combinations; oral
2.4
34.1
343
1824
E000007, ,
ATC
4.1
33.7
100
267
D72.1
ICD-10 Finland
Eosinophilia
36.6
33.1
42
12
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
10.4
32.9
37
37
DJD20
NOMESCO Finland
Plastic repair of septum of nose
4.9
32.1
74
162
XG405
NOMESCO Finland
Education on PEF monitoring
10.1
31.4
36
37
J01MA12
ATC
levofloxacin; systemic
2.8
31.1
194
817
D11AX15
ATC
[U] pimecrolimus
48.1
30.8
37
8
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
4.7
30.7
74
168
T78.3
ICD-10 Finland
Angioneurotic oedema
9.4
30.5
37
41
S01GX08
ATC
ketotifen; ophthalmic
4.1
30.4
89
235
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
33.9
30.2
39
12
J01FA15
ATC
telithromycin; oral
3.1
29.8
142
515
J34.2
ICD-10 Finland
Deviated nasal septum
3.8
29.5
97
278
TGC00
NOMESCO Finland
Bronchial lavation
6.5
29.4
49
79
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.9
29.4
91
250
3DX05, ,
NOMESCO Finland
+∞
29.3
28
*
A02BC05
ATC
esomeprazole; systemic
2.2
29.0
416
2528
D07BC01
ATC
betamethasone and antiseptics; topical
3.0
29.0
148
558
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
28.5
258
1293
J01DC02
ATC
cefuroxime; systemic
3.8
28.4
91
256
4930A
ICD-9 Finland
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA SINE EXACERBATIONE]
10.3
28.4
32
32
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.4
28.2
259
1304
E000006, ,
ATC
3.6
28.0
99
298
J01FF01
ATC
clindamycin; systemic
2.3
27.8
296
1588
R03BB01
ATC
ipratropium bromide; inhalant
6.6
27.6
45
71
L04AA01
ATC
[U] ciclosporin
10.7
27.2
30
29
J01DB01
ATC
cefalexin; oral
3.3
26.8
806
6587
R06.2
ICD-10 Finland
Wheezing
4.1
26.4
76
198
GD1AD
NOMESCO Finland
Thorax CT examination
3.8
26.2
85
241
R03DX11
ATC
tezepelumab; systemic
+∞
26.2
25
*
L50.0
ICD-10 Finland
Allergic urticaria
5.2
25.9
55
112
R03BC03
ATC
nedocromil; inhalant
3.5
25.7
95
294
L04AX01
ATC
azathioprine; systemic
4.3
25.5
68
167
R01AD59
ATC
mometasone, combinations; nasal
3.0
24.6
121
445
D07AC14
ATC
methylprednisolone aceponate; topical
3.9
24.4
74
200
4939X
ICD-9 Finland
Asthma, unspecified[ASTHMA BRONCHIALE NUD]
8.1
24.4
33
42
A02BC02
ATC
pantoprazole; systemic
2.2
24.3
637
4755
DPW99
NOMESCO Finland
Other operation on frontal or sphenoidal sinus
69.4
23.9
27
*
DHA10
NOMESCO Finland
Biopsy of cavity of nose
9.9
23.3
27
28
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
23.2
100
340
J33.1
ICD-10 Finland
Polypoid sinus degeneration
85.7
22.8
25
*
R03BB07
ATC
umeclidinium bromide; inhalant
19.6
22.7
34
18
D07CC01
ATC
betamethasone and antibiotics; topical
2.5
22.0
154
678
R06AX18
ATC
acrivastine; oral
5.0
21.7
48
101
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
4.2
21.2
58
145
J02AC01
ATC
fluconazole; systemic
2.0
21.2
415
2738
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.0
20.8
298
1760
N02AJ06
ATC
codeine and paracetamol; systemic
1.9
20.7
448
3048
G47.3
ICD-10 Finland
Sleep apnoea
2.1
20.4
256
1437
WW200
NOMESCO Finland
Immunization
4.8
20.3
47
103
A07AA02
ATC
nystatin; oral
3.7
20.1
67
193
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
27.8
20.1
27
10
D07XC01
ATC
betamethasone; topical
2.6
20.0
132
564
GX1E5
NOMESCO Finland
Flow volume spirometry and bronchodilation test
18.2
19.7
30
17
L26
ICD-10 Finland
Exfoliative dermatitis
107.4
19.6
21
*
J01DA01
ATC
[U] cefalexin
2.0
19.6
580
4348
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
4.5
19.5
49
115
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.1
19.3
230
1264
A92
ICPC
Allergy/allergic reaction NOS
3.8
19.0
60
167
N02AX02
ATC
tramadol; systemic, rectal
1.9
18.5
394
2637
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
18.5
264
1546
R05
ICD-10 Finland
Cough
2.1
18.4
231
1290
4930B
ICD-9 Finland
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA CUM EXACERBATIONE]
16.6
18.4
29
18
T78.2
ICD-10 Finland
Anaphylactic shock, unspecified
6.1
17.9
31
52
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.4
17.8
139
640
4222
FHL
Endonasal etmoidectomy
20.6
17.8
26
13
L23.2
ICD-10 Finland
Allergic contact dermatitis due to cosmetics
6.9
17.5
27
40
O99.5
ICD-10 Finland
Diseases of the respiratory system complicating pregnancy, childbirth and the puerperium
7.9
17.5
24
31
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
4.9
17.4
39
83
H65.2
ICD-10 Finland
Chronic serous otitis media
6.3
17.3
29
47
J32.8
ICD-10 Finland
Other chronic sinusitis
17.8
17.0
26
15
D07XB05
ATC
dexamethasone; topical
4.5
16.5
41
95
Z76.0
ICD-10 Finland
Issue of repeat prescription
1.9
16.5
295
1851
J02AC02
ATC
itraconazole; systemic
2.1
16.5
178
936
UDC00
NOMESCO Finland
Ear microscopy
2.9
16.5
83
308
SPAT1254
SPAT
Administration of medicine
2.3
16.3
133
624
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
4.7
16.2
38
84
S01AD03
ATC
aciclovir; ophthalmic
4.0
15.9
46
120
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.7
15.9
88
343
TDW99
NOMESCO Finland
Other minor procedure in surgery of ear, nose and larynx
4.2
15.8
43
107
J82
ICD-10 Finland
Pulmonary eosinophilia, not elsewhere classified
61.1
15.8
18
*
A02BA02
ATC
ranitidine; systemic
2.2
15.6
157
802
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.8
15.6
568
4391
TQX05
NOMESCO Finland
Skin puncture, unspecified location
29.2
15.2
20
7
4711A
ICD-9 Finland
Nasal polyps, Polypoid sinus degeneration
23.9
15.2
21
9
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
2.7
15.0
84
329
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
4.1
15.0
42
107
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.8
15.0
413
2934
R05
ICPC
Cough
1.9
14.9
258
1594
J01MA02
ATC
ciprofloxacin; systemic
1.8
14.9
323
2140
E000004, ,
ATC
5.0
14.8
32
66
J04BA02
ATC
dapsone; oral
18.8
14.7
22
12
J01.1
ICD-10 Finland
Acute frontal sinusitis
4.4
14.4
36
84
N02BE01
ATC
paracetamol; systemic, rectal
2.5
14.4
807
7090
XQ820
NOMESCO Finland
Exposure to medicinal substance
17.3
14.3
22
13
D07CB01
ATC
triamcinolone and antibiotics; topical
5.2
14.2
29
57
3029
Kela drug reimbursment
Upadacitinib
14.7
14.1
23
16
J05AB01
ATC
aciclovir; systemic
1.9
14.0
219
1305
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
14.0
306
2022
J01DA08
ATC
[U] cefaclor
2.1
13.9
141
720
D07AB01
ATC
clobetasone; topical
3.9
13.9
42
113
L04AF03
ATC
upadacitinib; oral
24.2
13.8
19
8
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.8
13.8
249
1554
H10.1
ICD-10 Finland
Acute atopic conjunctivitis
3.6
13.6
45
129
L30.3
ICD-10 Finland
Infective dermatitis
3.4
13.6
49
149
3089, ,
Kela drug reimbursment
+∞
13.6
13
*
L20.8
ICD-10 Finland
Other atopic dermatitis
5.1
13.4
28
56
R03AK03
ATC
[U] fenoterol and ipratropium bromide
3.8
13.3
41
112
J01CA04
ATC
amoxicillin; systemic
2.1
13.2
772
6714
A02BC01
ATC
omeprazole; systemic
1.8
13.2
231
1425
XG404
NOMESCO Finland
Peak expiratory flow (PEF) measurement
15.3
13.1
21
14
R03BC01
ATC
cromoglicic acid; inhalant
4.7
13.1
30
65
DCA10
NOMESCO Finland
Paracentesis of tympanic membrane
4.7
13.1
30
65
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
13.0
233
1446
A46
ICD-10 Finland
Erysipelas
2.2
12.8
122
607
J05AB11
ATC
valaciclovir; oral
2.0
12.8
151
815
49302
ICD-8 Finland
Asthma, Rhinitis allergica cum asthmate bronchiali
14.3
12.8
21
15
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
5.2
12.7
26
51
ZX114
NOMESCO Finland
Intramuscular
5.0
12.7
27
55
J34.3
ICD-10 Finland
Hypertrophy of nasal turbinates
4.0
12.6
36
93
SPAT1058
SPAT
PEF monitoring instruction
2.6
12.6
77
315
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.2
12.6
108
515
J01.9
ICD-10 Finland
Acute sinusitis, unspecified
2.8
12.6
65
244
4AC06, ,
NOMESCO Finland
+∞
12.5
12
*
J20
ICD-10 Finland
Acute bronchitis
2.2
12.2
117
584
S02
ICPC
Pruritus
3.2
12.1
49
160
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
27.1
12.1
16
6
J01DA09
ATC
[U] cefadroxil
1.8
12.0
251
1625
H66.9
ICD-10 Finland
Otitis media, unspecified
2.4
12.0
90
405
M05BA04
ATC
alendronic acid; oral
2.8
12.0
62
233
M79.6
ICD-10 Finland
Pain in limb
1.7
12.0
408
3011
4224
FHL
Endonasal anthrostomy
5.9
11.8
21
36
S88
ICPC
Dermatitis contact/allergic
4.0
11.8
33
84
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.6
11.8
70
283
B00.10
ICD-10 Finland
Herpes simplex facialis
5.6
11.7
22
40
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
4.3
11.6
30
72
DHB40
NOMESCO Finland
Conchotomy
23.2
11.6
16
7
DMB00
NOMESCO Finland
Endonasal trephine of maxillary antrum
8.8
11.6
24
28
S98
ICPC
Urticaria
10.2
11.5
22
22
A02BC03
ATC
lansoprazole; oral
1.8
11.5
238
1535
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
1.7
11.5
282
1907
J30.4
ICD-10 Finland
Allergic rhinitis, unspecified
2.8
11.3
58
217
DMB10
NOMESCO Finland
Radical maxillary antrotomy
17.3
11.2
17
10
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.6
11.2
396
2935
GX2C5
NOMESCO Finland
Short-lasting oximetry
12.9
11.2
19
15
J30.0
ICD-10 Finland
Vasomotor rhinitis
3.7
11.2
35
97
R01AD
ATC
Corticosteroids
8.2
11.1
24
30
R78
ICPC
Acute bronchitis/bronchiolitis
4.0
11.1
31
79
R5140
NOMESCO Finland
Monitoring the use of the aid
2.1
11.0
112
572
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
3.8
10.9
33
89
R60.9
ICD-10 Finland
Oedema, unspecified
2.8
10.9
54
199
S01
ICPC
Pain/tenderness of skin
2.9
10.8
52
188
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
4.4
10.8
27
63
J01.4
ICD-10 Finland
Acute pansinusitis
5.7
10.7
20
36
R81
ICPC
Pneumonia
3.2
10.7
43
140
J40
ICD-10 Finland
Bronchitis, not specified as acute or chronic
3.4
10.6
39
120
Z3231
NOMESCO Finland
Registered nurse
1.7
10.6
234
1531
B07.9
ICD-10 Finland
Verruca simplex
2.9
10.5
49
174
WXQ26
NOMESCO Finland
UVB broad spectrum light therapy
+∞
10.4
10
*
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.6
10.4
322
2299
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
4.0
10.4
29
74
ZX110
NOMESCO Finland
Intracutaneous
32.9
10.3
13
*
R03AK
ATC
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
19.0
10.3
15
8
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
10.3
345
2511
M81.4
ICD-10 Finland
Drug-induced osteoporosis
13.3
10.2
17
13
DFF00
NOMESCO Finland
Pure tone audiometry
2.2
10.1
88
422
GD1AA, ,
SPAT
1.8
10.1
186
1155
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
12.4
9.9
17
14
H04.10
ICD-10 Finland
Dry eye syndrome
2.0
9.7
120
656
R06AX12
ATC
terfenadine; oral
2.7
9.7
52
200
S01GX02
ATC
levocabastine; ophthalmic
2.4
9.6
68
298
H66.0
ICD-10 Finland
Acute suppurative otitis media
2.1
9.6
97
493
Z71.8
ICD-10 Finland
Other specified counselling
1.6
9.6
332
2425
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
4.9
9.6
21
44
H66
ICD-10 Finland
Suppurative and unspecified otitis media
3.4
9.5
34
103
L29.9
ICD-10 Finland
Pruritus, unspecified
3.4
9.5
34
103
J01DA06
ATC
[U] cefuroxime
1.9
9.5
141
819
R10.1
ICD-10 Finland
Pain localized to upper abdomen
1.8
9.5
176
1094
3006
Kela drug reimbursment
Baricitinib
17.8
9.4
14
8
XG488
NOMESCO Finland
Other provokation of respiratroy tract
30.4
9.4
12
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.1
9.4
94
477
X58
ICD-10 Finland
Exposure to other specified factors
1.8
9.3
157
950
I45.9
ICD-10 Finland
Conduction disorder, unspecified
13.8
9.2
15
11
X59
ICD-10 Finland
Exposure to unspecified factor
1.7
9.2
181
1143
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
2.7
9.2
48
182
R49.08
ICD-10 Finland
Other specified dysphonia
3.6
9.1
30
86
DPA20
NOMESCO Finland
Trephine of frontal sinus
15.8
9.0
14
9
V01AA02
ATC
grass pollen; parenteral
15.8
9.0
14
9
UJF32
NOMESCO Finland
Coloscopy
1.7
9.0
195
1263
ZXE00
NOMESCO Finland
One hour or less
1.6
8.7
326
2410
R75
ICPC
Sinusitis acute/chronic
2.4
8.7
61
267
WX002
NOMESCO Finland
Sedation and analgesia
1.8
8.7
149
904
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.3
8.6
63
281
L50.2
ICD-10 Finland
Urticaria due to cold and heat
16.5
8.6
13
8
4226
FHL
Posterior radical surgery and possible etmoidectomy
10.2
8.5
16
16
L08.0
ICD-10 Finland
Pyoderma
10.2
8.5
16
16
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
2.3
8.4
66
303
L50.5
ICD-10 Finland
Cholinergic urticaria
+∞
8.3
8
*
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
8.3
175
1123
S01GX04
ATC
nedocromil; ophthalmic
3.9
8.3
24
63
J01DB05
ATC
cefadroxil; oral
2.6
8.3
48
192
R51.80
ICD-10 Finland
Headache
1.7
8.3
167
1060
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
14.6
8.2
13
9
N03AX12
ATC
[U] gabapentin; oral
1.8
8.2
139
840
L03.9
ICD-10 Finland
Cellulitis, unspecified
3.6
8.2
26
73
R03AL08
ATC
vilanterol, umeclidinium bromide and fluticasone furoate; inhalant
4.6
8.1
19
42
R05FA02
ATC
opium derivatives and expectorants; systemic
1.5
8.1
322
2403
S01BA01
ATC
dexamethasone; ophthalmic
3.1
8.1
34
114
A01AB09
ATC
miconazole; local oral
2.2
8.1
71
342
N06AX11
ATC
mirtazapine; oral
1.5
8.1
299
2199
WX110
NOMESCO Finland
Infiltration anesthesia
1.6
8.0
664
5780
R05DA20
ATC
opium alkaloids and derivatives - combinations
1.6
8.0
219
1501
H72.0
ICD-10 Finland
Central perforation of tympanic membrane
3.9
8.0
23
60
R74
ICPC
Upper respiratory infection acute
1.5
8.0
358
2740
J37.0
ICD-10 Finland
Chronic laryngitis
2.9
8.0
38
137
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.7
8.0
172
1111
N06AX26
ATC
vortioxetine; oral
2.0
7.9
88
463
R60.0
ICD-10 Finland
Localized oedema
1.9
7.9
96
521
Z01.7
ICD-10 Finland
Laboratory examination
1.7
7.9
160
1015
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
1.8
7.9
116
670
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
2.7
7.9
41
155
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
4.7
7.9
18
39
H10.5
ICD-10 Finland
Blepharoconjunctivitis
3.4
7.8
27
80
SPAT1059
SPAT
Spirometry at the office
2.6
7.8
45
180
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.9
7.7
98
540
DNB10
NOMESCO Finland
Endonasal ethmoidectomy
45.4
7.7
9
*
B37.0
ICD-10 Finland
Candidal stomatitis
6.0
7.7
20
34
A02BC04
ATC
rabeprazole; oral
2.0
7.6
89
477
A03
ICPC
Fever
1.6
7.6
183
1214
L01.1
ICD-10 Finland
Impetiginization of other dermatoses
9.0
7.6
15
17
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.4
7.5
51
220
H10
ICD-10 Finland
Conjunctivitis
2.0
7.5
83
436
J01XC01
ATC
fusidic acid; systemic
4.3
7.5
19
45
V01AA05
ATC
tree pollen; parenteral
6.5
7.4
18
28
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.7
7.4
138
855
WX402
NOMESCO Finland
General anaesthesia
1.6
7.4
202
1381
3023
Kela drug reimbursment
Allergen extract of birch pollen (adults)
13.5
7.4
12
9
SPAT1149
SPAT
Suture or treatment of traumatic wound
1.9
7.4
89
482
Z01.1
ICD-10 Finland
Examination of ears and hearing
1.8
7.4
112
654
1543, ,
Kela drug reimbursment
+∞
7.3
7
*
4931A
ICD-9 Finland
Asthma, Intrinsic asthma[INTRINSIC ASTHMA SINE EXACERBATIONE]
9.5
7.3
14
15
T88.7
ICD-10 Finland
Unspecified adverse effect of drug or medicament
3.9
7.3
21
55
T78.0
ICD-10 Finland
Anaphylactic shock due to adverse food reaction
15.9
7.2
11
7
SPAT1255
SPAT
Intravenous administration of medicine
2.3
7.2
53
237
H26.3
ICD-10 Finland
Drug-induced cataract
7.4
7.2
16
22
WVA20
NOMESCO Finland
Medicine administration
2.9
7.2
33
117
N06AX12
ATC
bupropion; oral
1.9
7.2
89
487
L95.8
ICD-10 Finland
Other vasculitis limited to skin
20.2
7.1
10
5
T88.6
ICD-10 Finland
Anaphylactic shock due to adverse effect of correct drug or medicament properly administered
20.2
7.1
10
5
R03BA07
ATC
mometasone; inhalant
6.6
7.1
17
26
J32.1
ICD-10 Finland
Chronic frontal sinusitis
6.6
7.1
17
26
J39.9
ICD-10 Finland
Disease of upper respiratory tract, unspecified
12.1
7.1
12
10
L71.9
ICD-10 Finland
Rosacea, unspecified
3.0
7.0
30
102
H01.0
ICD-10 Finland
Blepharitis
2.0
7.0
75
390
J01
ICD-10 Finland
Acute sinusitis
2.1
7.0
62
300
4221
FHL
Polyp removal from the nasal cavity, sinus puncture or irrigation, or biopsy under general anesthesia or operating room
7.6
6.9
15
20
B00.0
ICD-10 Finland
Eczema herpeticum
7.6
6.9
15
20
R01AC07
ATC
nedocromil; nasal
13.9
6.9
11
8
SPAT1263
SPAT
Sampling
1.5
6.9
342
2653
H10.0
ICD-10 Finland
Mucopurulent conjunctivitis
2.0
6.9
75
393
ZYC01
NOMESCO Finland
Remote contact by phone
2.1
6.9
66
330
C09CA06
ATC
candesartan; oral
1.6
6.8
203
1413
WX780
NOMESCO Finland
Remote monitoring CPAP
2.3
6.8
51
230
S18
ICPC
Laceration/cut
1.5
6.8
380
3012
R09
ICPC
Sinus symptom/complaint
1.9
6.8
91
510
D06AX01
ATC
fusidic acid; topical
1.9
6.8
88
488
R83
ICPC
Respiratory infection other
1.5
6.8
273
2030
4732A
ICD-9 Finland
Chronic sinusitis, Ethmoidal
40.4
6.8
8
*
4931B
ICD-9 Finland
Asthma, Intrinsic asthma[INTRINSIC ASTHMA CUM EXACERBATIONE]
16.8
6.8
10
6
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
1.7
6.7
123
758
M03BX02
ATC
tizanidine; oral
1.5
6.7
561
4794
K04.5
ICD-10 Finland
Chronic apical periodontitis
1.5
6.6
236
1709
SFC01
NOMESCO Finland
Additional procedure necessary for restorative treatment
1.5
6.6
241
1753
EP1AE
NOMESCO Finland
Neck ultrasound examination
2.2
6.6
54
253
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
1.4
6.6
500
4188
K30
ICD-10 Finland
Functional dyspepsia
1.8
6.6
105
622
J01DC04
ATC
cefaclor; oral
3.9
6.6
19
50
H03.1*B00.5
ICD-10 Finland
Herpesviral dermatitis of eyelid
10.1
6.5
12
12
R29
ICPC
Respiratory symptom/complaint other
2.0
6.5
70
364
R06AE08, ,
ATC
5.4
6.5
18
34
UJF30
NOMESCO Finland
Ileoscopy through colon
1.9
6.5
89
504
H25.8
ICD-10 Finland
Other senile cataract
2.2
6.4
51
236
B44.1
ICD-10 Finland
Other pulmonary aspergillosis
70.3
6.4
7
*
A06AC01
ATC
ispaghula (psylla seeds); oral
1.5
6.4
200
1407
D07CA01
ATC
hydrocortisone and antibiotics; topical
1.7
6.4
112
682
AA3AI
NOMESCO Finland
Cone beam CT of facial bones
4.1
6.4
17
42
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
8.2
6.3
13
16
R49.8
ICD-10 Finland
Other and unspecified voice disturbances
5.6
6.3
17
31
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
1.6
6.3
152
1006
WX722
NOMESCO Finland
PEEP
2.5
6.3
39
162
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
18.2
6.3
9
5
3DX08, ,
NOMESCO Finland
+∞
6.3
6
*
R01AC01
ATC
cromoglicic acid; nasal
2.3
6.2
45
200
R05CB01
ATC
acetylcysteine; inhalant, oral
7.1
6.2
14
20
H10.9
ICD-10 Finland
Conjunctivitis, unspecified
1.9
6.2
73
392
Z04.9
ICD-10 Finland
Examination and observation for unspecified reason
2.4
6.2
40
169
R07
ICPC
Sneezing/nasal congestion
1.9
6.2
75
407
N06AX21
ATC
duloxetine; oral
1.7
6.1
114
705
SFA20
NOMESCO Finland
Two-surface restoration
1.4
6.1
545
4671
JN3AD
NOMESCO Finland
Abdominal CT examination
1.7
6.1
107
652
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.5
6.1
278
2112
L04AA44
ATC
[U] upadacitinib
10.1
6.0
11
11
J98.0
ICD-10 Finland
Diseases of bronchus, not elsewhere classified
10.1
6.0
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
2.9e+00
1.0e+50
1.6e+00
9.7e+00
2.4e+00
1.0e+50
1.0e+50
cases:99.89%
controls:97.90%
cases:100.00%
controls:90.37%
cases:84.53%
controls:52.87%
cases:99.89%
controls:2.68%
cases:92.15%
controls:52.41%
cases:100.00%
controls:90.21%
cases:100.00%
controls:97.09%
891
8733
1
187
892
8061
0
859
754
4716
138
4204
891
239
1
8681
822
4660
70
4231
858
7632
0
828
457
4531
0
136
Nonallergic asthma
J45.1 [45557625]
3.4e+00
4.0e+00
4.5e+00
1.0e+50
4.4e+00
4.0e+00
3.5e+00
cases:19.17%
controls:0.82%
cases:23.21%
controls:0.54%
cases:10.31%
controls:0.12%
cases:0.90%
controls:0.00%
cases:10.87%
controls:0.15%
cases:22.49%
controls:0.52%
cases:26.26%
controls:1.09%
171
73
721
8847
207
48
685
8872
92
11
800
8909
8
0
884
8920
97
13
795
8878
193
44
665
8416
120
51
337
4616
Predominantly allergic asthma
J45.0 [45557624]
3.2e+00
3.9e+00
4.3e+00
—
4.3e+00
3.8e+00
3.4e+00
cases:28.48%
controls:1.64%
cases:28.03%
controls:0.80%
cases:14.01%
controls:0.21%
—
—
cases:11.43%
controls:0.18%
cases:25.64%
controls:0.79%
cases:31.95%
controls:1.54%
254
146
638
8774
250
71
642
8849
125
19
767
8901
—
102
16
790
8875
220
67
638
8393
146
72
311
4595
Besnier prurigo
L20.0 [45562534]
2.8e+00
3.8e+00
4.8e+00
1.0e+50
4.9e+00
3.5e+00
2.9e+00
cases:20.96%
controls:1.58%
cases:24.66%
controls:0.70%
cases:12.22%
controls:0.11%
cases:4.82%
controls:0.00%
cases:14.80%
controls:0.12%
cases:22.49%
controls:0.87%
cases:25.60%
controls:1.84%
187
141
705
8779
220
62
672
8858
109
10
783
8910
43
0
849
8920
132
11
760
8880
193
74
665
8386
117
86
340
4581
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
3.3e+00
4.7e+00
3.9e+00
—
2.6e+00
3.4e+00
3.0e+00
cases:47.09%
controls:3.27%
cases:45.52%
controls:0.75%
cases:3.92%
controls:0.08%
—
—
cases:1.35%
controls:0.10%
cases:18.18%
controls:0.74%
cases:34.79%
controls:2.53%
420
292
472
8628
406
67
486
8853
35
7
857
8913
—
12
9
880
8882
156
63
702
8397
159
118
298
4549
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.2e+00
3.5e+00
4.3e+00
—
4.2e+00
3.3e+00
2.7e+00
cases:48.77%
controls:9.56%
cases:57.29%
controls:3.91%
cases:27.58%
controls:0.54%
—
—
cases:27.91%
controls:0.56%
cases:51.98%
controls:4.00%
cases:60.83%
controls:9.58%
435
853
457
8067
511
349
381
8571
246
48
646
8872
—
249
50
643
8841
446
338
412
8122
278
447
179
4220
Chronic pansinusitis
J32.4 [45581854]
4.5e+00
5.7e+00
—
1.0e+50
—
4.8e+00
4.2e+00
cases:13.79%
controls:0.18%
cases:14.35%
controls:0.06%
—
—
cases:0.90%
controls:0.00%
—
—
cases:13.40%
controls:0.13%
cases:14.88%
controls:0.26%
123
16
769
8904
128
5
764
8915
—
8
0
884
8920
—
115
11
743
8449
68
12
389
4655
formoterol and beclometasone
R03AK08 [43534839]
3.1e+00
3.2e+00
3.2e+00
1.0e+50
2.8e+00
3.2e+00
2.9e+00
cases:26.79%
controls:1.61%
cases:26.01%
controls:1.42%
cases:10.20%
controls:0.47%
cases:2.69%
controls:0.00%
cases:8.52%
controls:0.57%
cases:26.34%
controls:1.45%
cases:30.63%
controls:2.49%
239
144
653
8776
232
127
660
8793
91
42
801
8878
24
0
868
8920
76
51
816
8840
226
123
632
8337
140
116
317
4551
FEV1/FVC
19926-5 [3011505]
2.3e+00
3.3e+00
3.3e+00
—
2.2e+00
3.6e+00
3.3e+00
cases:28.14%
controls:3.83%
cases:25.45%
controls:1.26%
cases:2.13%
controls:0.08%
—
—
cases:1.35%
controls:0.16%
cases:25.52%
controls:0.93%
cases:36.54%
controls:2.01%
251
342
641
8578
227
112
665
8808
19
7
873
8913
—
12
14
880
8877
219
79
639
8381
167
94
290
4573
FEV1
20150-9 [3024653]
2.3e+00
3.3e+00
3.3e+00
—
2.2e+00
3.6e+00
3.3e+00
cases:28.14%
controls:3.83%
cases:25.45%
controls:1.26%
cases:2.13%
controls:0.08%
—
—
cases:1.35%
controls:0.16%
cases:25.52%
controls:0.93%
cases:36.54%
controls:2.01%
251
342
641
8578
227
112
665
8808
19
7
873
8913
—
12
14
880
8877
219
79
639
8381
167
94
290
4573
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
2.3e+00
3.3e+00
3.3e+00
—
2.2e+00
3.6e+00
3.3e+00
cases:28.14%
controls:3.83%
cases:25.45%
controls:1.26%
cases:2.13%
controls:0.08%
—
—
cases:1.35%
controls:0.16%
cases:25.52%
controls:0.93%
cases:36.54%
controls:2.01%
251
342
641
8578
227
112
665
8808
19
7
873
8913
—
12
14
880
8877
219
79
639
8381
167
94
290
4573
montelukast; oral
R03DC03 [21603356]
3.1e+00
3.5e+00
3.2e+00
—
2.4e+00
3.0e+00
2.7e+00
cases:51.12%
controls:4.52%
cases:45.40%
controls:2.56%
cases:10.76%
controls:0.48%
—
—
cases:7.51%
controls:0.75%
cases:35.08%
controls:2.51%
cases:38.29%
controls:3.99%
456
403
436
8517
405
228
487
8692
96
43
796
8877
—
67
67
825
8824
301
212
557
8248
175
186
282
4481
tiotropium bromide; inhalant
R03BB04 [21603296]
3.0e+00
3.3e+00
2.8e+00
1.0e+50
2.9e+00
3.0e+00
3.0e+00
cases:30.16%
controls:2.11%
cases:26.46%
controls:1.35%
cases:7.74%
controls:0.50%
cases:2.24%
controls:0.00%
cases:7.17%
controls:0.44%
cases:22.03%
controls:1.45%
cases:29.98%
controls:2.14%
269
188
623
8732
236
120
656
8800
69
45
823
8875
20
0
872
8920
64
39
828
8852
189
123
669
8337
137
100
320
4567
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
2.8e+00
3.2e+00
3.1e+00
1.0e+50
3.0e+00
3.0e+00
2.7e+00
cases:5.16%
controls:0.33%
cases:8.52%
controls:0.39%
cases:3.70%
controls:0.17%
cases:1.12%
controls:0.00%
cases:3.14%
controls:0.17%
cases:9.56%
controls:0.53%
cases:14.44%
controls:1.18%
46
29
846
8891
76
35
816
8885
33
15
859
8905
10
0
882
8920
28
15
864
8876
82
45
776
8415
66
55
391
4612
Polyp of nasal cavity
J33.0 [45562447]
4.2e+00
4.8e+00
—
1.0e+50
—
4.8e+00
3.7e+00
cases:16.93%
controls:0.30%
cases:16.48%
controls:0.17%
—
—
cases:1.01%
controls:0.00%
—
—
cases:14.80%
controls:0.14%
cases:11.38%
controls:0.32%
151
27
741
8893
147
15
745
8905
—
9
0
883
8920
—
127
12
731
8448
52
15
405
4652
FVC percent change Respiratory system
69982-7 [42868471]
2.2e+00
3.2e+00
3.4e+00
—
1.9e+00
3.3e+00
3.1e+00
cases:24.10%
controls:3.37%
cases:21.08%
controls:1.11%
cases:1.68%
controls:0.06%
—
—
cases:1.01%
controls:0.15%
cases:17.37%
controls:0.77%
cases:28.45%
controls:1.84%
215
301
677
8619
188
99
704
8821
15
5
877
8915
—
9
13
883
8878
149
65
709
8395
130
86
327
4581
FEV1 --post bronchodilation
20155-8 [3023550]
2.2e+00
3.2e+00
3.4e+00
—
1.9e+00
3.3e+00
3.1e+00
cases:24.10%
controls:3.37%
cases:21.08%
controls:1.11%
cases:1.68%
controls:0.06%
—
—
cases:1.01%
controls:0.15%
cases:17.37%
controls:0.77%
cases:28.45%
controls:1.84%
215
301
677
8619
188
99
704
8821
15
5
877
8915
—
9
13
883
8878
149
65
709
8395
130
86
327
4581
FEV1/FVC --post bronchodilation
69970-2 [42868459]
2.2e+00
3.2e+00
3.4e+00
—
1.9e+00
3.3e+00
3.1e+00
cases:24.10%
controls:3.37%
cases:21.08%
controls:1.11%
cases:1.68%
controls:0.06%
—
—
cases:1.01%
controls:0.15%
cases:17.37%
controls:0.77%
cases:28.45%
controls:1.84%
215
301
677
8619
188
99
704
8821
15
5
877
8915
—
9
13
883
8878
149
65
709
8395
130
86
327
4581
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
2.2e+00
3.2e+00
3.4e+00
—
1.9e+00
3.3e+00
3.1e+00
cases:24.10%
controls:3.37%
cases:21.08%
controls:1.11%
cases:1.68%
controls:0.06%
—
—
cases:1.01%
controls:0.15%
cases:17.37%
controls:0.77%
cases:28.45%
controls:1.84%
215
301
677
8619
188
99
704
8821
15
5
877
8915
—
9
13
883
8878
149
65
709
8395
130
86
327
4581
FEV1 percent change
69983-5 [42868472]
2.2e+00
3.2e+00
3.4e+00
—
1.9e+00
3.3e+00
3.1e+00
cases:24.10%
controls:3.37%
cases:21.08%
controls:1.11%
cases:1.68%
controls:0.06%
—
—
cases:1.01%
controls:0.15%
cases:17.37%
controls:0.77%
cases:28.45%
controls:1.84%
215
301
677
8619
188
99
704
8821
15
5
877
8915
—
9
13
883
8878
149
65
709
8395
130
86
327
4581
Exhaled nitric oxide analysis
GX1L5 [2001303831]
3.5e+00
4.1e+00
—
—
—
4.8e+00
4.6e+00
cases:2.24%
controls:0.07%
cases:5.04%
controls:0.09%
—
—
—
—
—
—
cases:7.93%
controls:0.07%
cases:16.19%
controls:0.19%
20
6
872
8914
45
8
847
8912
—
—
—
68
6
790
8454
74
9
383
4658
Pulmonary Disease
29 [38004472]
2.1e+00
2.8e+00
3.3e+00
—
3.3e+00
2.7e+00
2.6e+00
cases:55.38%
controls:12.70%
cases:54.26%
controls:6.47%
cases:22.65%
controls:1.03%
—
—
cases:23.43%
controls:1.11%
cases:51.52%
controls:6.48%
cases:64.33%
controls:11.74%
494
1133
398
7787
484
577
408
8343
202
92
690
8828
—
209
99
683
8792
442
548
416
7912
294
548
163
4119
Asthma
J45 [45596282]
2.3e+00
3.3e+00
3.6e+00
—
2.2e+00
3.0e+00
2.1e+00
cases:26.01%
controls:3.28%
cases:24.55%
controls:1.20%
cases:5.27%
controls:0.16%
—
—
cases:1.23%
controls:0.13%
cases:19.70%
controls:1.19%
cases:24.07%
controls:3.64%
232
293
660
8627
219
107
673
8813
47
14
845
8906
—
11
12
881
8879
169
101
689
8359
110
170
347
4497
Bronchiectasis
J47 [45605889]
2.4e+00
2.7e+00
2.9e+00
—
3.0e+00
2.5e+00
2.7e+00
cases:2.35%
controls:0.21%
cases:2.58%
controls:0.18%
cases:1.01%
controls:0.06%
—
—
cases:1.12%
controls:0.06%
cases:2.45%
controls:0.21%
cases:4.38%
controls:0.30%
21
19
871
8901
23
16
869
8904
9
5
883
8915
—
10
5
882
8886
21
18
837
8442
20
14
437
4653
formoterol and fluticasone
R03AK11 [44819166]
3.1e+00
3.3e+00
—
1.0e+50
3.5e+00
3.2e+00
3.0e+00
cases:11.21%
controls:0.58%
cases:8.07%
controls:0.33%
—
—
cases:0.90%
controls:0.00%
cases:2.58%
controls:0.08%
cases:6.64%
controls:0.28%
cases:7.66%
controls:0.41%
100
52
792
8868
72
29
820
8891
—
8
0
884
8920
23
7
869
8884
57
24
801
8436
35
19
422
4648
Aspergillus fumigatus IgE Ab [Units/volume] in Serum
6025-1 [3011951]
3.9e+00
4.8e+00
—
—
—
3.7e+00
3.5e+00
cases:14.24%
controls:0.35%
cases:10.65%
controls:0.10%
—
—
—
—
—
—
cases:2.80%
controls:0.07%
cases:9.41%
controls:0.30%
127
31
765
8889
95
9
797
8911
—
—
—
24
6
834
8454
43
14
414
4653
prednisolone; oral, parenteral
H02AB06 [21602734]
3.0e+00
3.4e+00
2.7e+00
—
1.7e+00
2.2e+00
2.3e+00
cases:77.69%
controls:14.57%
cases:63.68%
controls:5.47%
cases:11.10%
controls:0.84%
—
—
cases:5.27%
controls:1.01%
cases:32.87%
controls:5.14%
cases:56.67%
controls:12.00%
693
1300
199
7620
568
488
324
8432
99
75
793
8845
—
47
90
845
8801
282
435
576
8025
259
560
198
4107
Chronic maxillary sinusitis
J32.0 [45586667]
2.8e+00
3.8e+00
—
—
3.3e+00
3.0e+00
2.4e+00
cases:15.70%
controls:1.14%
cases:11.55%
controls:0.29%
—
—
—
—
cases:1.57%
controls:0.06%
cases:8.39%
controls:0.46%
cases:12.04%
controls:1.29%
140
102
752
8818
103
26
789
8894
—
—
14
5
878
8886
72
39
786
8421
55
60
402
4607
prednisolone
A07EA01 [21600653]
3.0e+00
3.4e+00
2.7e+00
—
1.7e+00
2.2e+00
2.3e+00
cases:77.69%
controls:14.73%
cases:63.68%
controls:5.49%
cases:11.10%
controls:0.84%
—
—
cases:5.27%
controls:1.01%
cases:32.87%
controls:5.15%
cases:56.67%
controls:12.02%
693
1314
199
7606
568
490
324
8430
99
75
793
8845
—
47
90
845
8801
282
436
576
8024
259
561
198
4106
Asthma, unspecified
J45.9 [45562456]
2.6e+00
2.6e+00
2.7e+00
—
3.0e+00
2.3e+00
1.9e+00
cases:40.02%
controls:4.72%
cases:24.89%
controls:2.34%
cases:6.73%
controls:0.47%
—
—
cases:9.19%
controls:0.48%
cases:20.16%
controls:2.39%
cases:29.98%
controls:5.89%
357
421
535
8499
222
209
670
8711
60
42
832
8878
—
82
43
810
8848
173
202
685
8258
137
275
320
4392
Atopic dermatitis
L20 [45557698]
2.4e+00
3.8e+00
3.6e+00
—
—
3.0e+00
2.3e+00
cases:8.07%
controls:0.77%
cases:10.87%
controls:0.27%
cases:2.02%
controls:0.06%
—
—
—
—
cases:4.55%
controls:0.24%
cases:7.66%
controls:0.81%
72
69
820
8851
97
24
795
8896
18
5
874
8915
—
—
39
20
819
8440
35
38
422
4629
tacrolimus
D11AH01 [21602338]
2.3e+00
2.5e+00
2.9e+00
—
2.8e+00
2.4e+00
2.0e+00
cases:17.15%
controls:2.00%
cases:8.97%
controls:0.77%
cases:1.68%
controls:0.09%
—
—
cases:2.02%
controls:0.12%
cases:8.97%
controls:0.86%
cases:14.88%
controls:2.23%
153
178
739
8742
80
69
812
8851
15
8
877
8912
—
18
11
874
8880
77
73
781
8387
68
104
389
4563
hydrocortisone; oral, parenteral
H02AB09 [21602737]
2.1e+00
2.7e+00
2.6e+00
—
2.4e+00
2.7e+00
2.2e+00
cases:13.45%
controls:1.89%
cases:9.42%
controls:0.71%
cases:2.02%
controls:0.15%
—
—
cases:1.46%
controls:0.13%
cases:8.62%
controls:0.64%
cases:15.10%
controls:2.01%
120
169
772
8751
84
63
808
8857
18
13
874
8907
—
13
12
879
8879
74
54
784
8406
69
94
388
4573
vilanterol and fluticasone furoate
R03AK10 [43534841]
2.6e+00
2.6e+00
2.4e+00
1.0e+50
2.0e+00
2.5e+00
2.5e+00
cases:16.37%
controls:1.41%
cases:11.55%
controls:1.01%
cases:4.04%
controls:0.37%
cases:1.35%
controls:0.00%
cases:3.36%
controls:0.45%
cases:12.24%
controls:1.13%
cases:18.16%
controls:1.76%
146
126
746
8794
103
90
789
8830
36
33
856
8887
12
0
880
8920
30
40
862
8851
105
96
753
8364
83
82
374
4585
Status asthmaticus
J46 [45591560]
3.6e+00
4.1e+00
—
—
—
3.5e+00
3.4e+00
cases:8.86%
controls:0.26%
cases:5.49%
controls:0.10%
—
—
—
—
—
—
cases:2.68%
controls:0.08%
cases:9.63%
controls:0.36%
79
23
813
8897
49
9
843
8911
—
—
—
23
7
835
8453
44
17
413
4650
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
3.9e+00
3.9e+00
—
1.0e+50
—
3.6e+00
3.0e+00
cases:8.07%
controls:0.18%
cases:5.16%
controls:0.11%
—
—
cases:0.78%
controls:0.00%
—
—
cases:3.85%
controls:0.11%
cases:4.38%
controls:0.24%
72
16
820
8904
46
10
846
8910
—
7
0
885
8920
—
33
9
825
8451
20
11
437
4656
salbutamol and ipratropium bromide
R03AL02 [43534844]
3.3e+00
3.6e+00
—
—
—
3.4e+00
3.6e+00
cases:5.27%
controls:0.20%
cases:3.59%
controls:0.10%
—
—
—
—
—
—
cases:2.68%
controls:0.09%
cases:6.78%
controls:0.19%
47
18
845
8902
32
9
860
8911
—
—
—
23
8
835
8452
31
9
426
4658
Case Management Agency
251B00000X [38004193]
1.8e+00
4.4e+00
1.6e+00
2.0e+00
1.4e+00
2.6e+00
1.0e+50
cases:99.44%
controls:96.61%
cases:99.89%
controls:91.24%
cases:79.15%
controls:44.15%
cases:18.83%
controls:2.98%
cases:76.01%
controls:44.84%
cases:99.53%
controls:94.05%
cases:100.00%
controls:99.31%
887
8618
5
302
891
8139
1
781
706
3938
186
4982
168
266
724
8654
678
3987
214
4904
854
7957
4
503
457
4635
0
32
levocetirizine; oral
R06AE09 [21603498]
1.9e+00
2.3e+00
2.6e+00
1.0e+50
2.5e+00
2.2e+00
2.3e+00
cases:13.68%
controls:2.37%
cases:11.10%
controls:1.24%
cases:3.36%
controls:0.26%
cases:0.67%
controls:0.00%
cases:2.24%
controls:0.19%
cases:8.97%
controls:1.10%
cases:12.47%
controls:1.44%
122
211
770
8709
99
111
793
8809
30
23
862
8897
6
0
886
8920
20
17
872
8874
77
93
781
8367
57
67
400
4600
Urticaria, unspecified
L50.9 [45562541]
2.4e+00
4.8e+00
—
—
—
3.6e+00
2.7e+00
cases:6.28%
controls:0.61%
cases:9.64%
controls:0.09%
—
—
—
—
—
—
cases:5.13%
controls:0.14%
cases:7.00%
controls:0.51%
56
54
836
8866
86
8
806
8912
—
—
—
44
12
814
8448
32
24
425
4643
Supplier / Service Provider
OMOP5117446 [33004]
5.0e-01
1.5e+00
1.6e+00
—
2.6e+00
3.7e+00
3.5e+00
cases:53.48%
controls:41.12%
cases:31.05%
controls:9.30%
cases:2.80%
controls:0.56%
—
—
cases:2.13%
controls:0.16%
cases:27.86%
controls:0.93%
cases:40.70%
controls:2.01%
477
3668
415
5252
277
830
615
8090
25
50
867
8870
—
19
14
873
8877
239
79
619
8381
186
94
271
4573
Teaching
WZC30 [2001310891]
1.4e+00
2.3e+00
3.2e+00
—
3.5e+00
1.4e+00
1.5e+00
cases:13.79%
controls:3.79%
cases:13.00%
controls:1.47%
cases:5.72%
controls:0.24%
—
—
cases:7.29%
controls:0.24%
cases:5.83%
controls:1.51%
cases:16.41%
controls:4.01%
123
338
769
8582
116
131
776
8789
51
21
841
8899
—
65
21
827
8870
50
128
808
8332
75
187
382
4480
Mixed asthma
J45.8 [45548118]
2.9e+00
3.8e+00
—
—
—
3.4e+00
3.2e+00
cases:6.39%
controls:0.36%
cases:5.72%
controls:0.13%
—
—
—
—
—
—
cases:4.78%
controls:0.17%
cases:5.03%
controls:0.21%
57
32
835
8888
51
12
841
8908
—
—
—
41
14
817
8446
23
10
434
4657
triamcinolone and antiseptics
D07BB03 [21602150]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
chlorhexidine
D09AA12 [21602275]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
chlorhexidine, combinations
D08AC52 [21602208]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
chlorhexidine
S03AA04 [21605193]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
chlorhexidine
S02AA09 [21605155]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.65%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
55
817
8405
35
106
422
4561
hydrocortisone and antiseptics
D07BA04 [21602146]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.66%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
56
817
8404
35
106
422
4561
hydrocortisone
D07XA01 [21602180]
2.0e+00
2.6e+00
2.6e+00
—
2.9e+00
2.0e+00
1.3e+00
cases:14.35%
controls:2.29%
cases:7.74%
controls:0.65%
cases:1.35%
controls:0.10%
—
—
cases:1.23%
controls:0.07%
cases:4.78%
controls:0.66%
cases:7.66%
controls:2.27%
128
204
764
8716
69
58
823
8862
12
9
880
8911
—
11
6
881
8885
41
56
817
8404
35
106
422
4561
Eosinophils [#/volume] in Blood
26449-9 [3013115]
2.1e+00
3.3e+00
1.7e+00
1.9e+00
1.3e+00
2.5e+00
2.4e+00
cases:74.55%
controls:26.93%
cases:82.06%
controls:14.14%
cases:12.67%
controls:2.62%
cases:0.67%
controls:0.10%
cases:9.87%
controls:2.81%
cases:67.25%
controls:13.87%
cases:80.31%
controls:27.92%
665
2402
227
6518
732
1261
160
7659
113
234
779
8686
6
9
886
8911
88
250
804
8641
577
1173
281
7287
367
1303
90
3364
Inpatient Hospital
21 [8717]
5.3e-01
1.6e+00
3.9e+00
—
3.1e+00
2.3e+00
1.9e+00
cases:31.95%
controls:21.69%
cases:14.69%
controls:3.42%
cases:14.91%
controls:0.36%
—
—
cases:9.87%
controls:0.47%
cases:16.78%
controls:2.06%
cases:24.73%
controls:4.65%
285
1935
607
6985
131
305
761
8615
133
32
759
8888
—
88
42
804
8849
144
174
714
8286
113
217
344
4450
Urticaria
L50 [45543371]
2.4e+00
4.7e+00
—
—
—
3.2e+00
3.0e+00
cases:2.58%
controls:0.24%
cases:9.64%
controls:0.10%
—
—
—
—
—
—
cases:1.75%
controls:0.07%
cases:5.25%
controls:0.28%
23
21
869
8899
86
9
806
8911
—
—
—
15
6
843
8454
24
13
433
4654
ciclesonide; nasal
R01AD13 [43534836]
2.2e+00
2.2e+00
2.3e+00
—
2.1e+00
2.2e+00
2.2e+00
cases:19.73%
controls:2.62%
cases:14.35%
controls:1.76%
cases:3.81%
controls:0.39%
—
—
cases:3.36%
controls:0.40%
cases:13.29%
controls:1.74%
cases:17.07%
controls:2.21%
176
234
716
8686
128
157
764
8763
34
35
858
8885
—
30
36
862
8855
114
147
744
8313
78
103
379
4564
ciclesonide; inhalant
R03BA08 [21603291]
2.2e+00
2.2e+00
2.3e+00
—
2.1e+00
2.2e+00
2.2e+00
cases:19.73%
controls:2.62%
cases:14.35%
controls:1.76%
cases:3.81%
controls:0.39%
—
—
cases:3.36%
controls:0.40%
cases:13.29%
controls:1.74%
cases:17.07%
controls:2.21%
176
234
716
8686
128
157
764
8763
34
35
858
8885
—
30
36
862
8855
114
147
744
8313
78
103
379
4564
ciclosporin; oral, parenteral
L04AD01 [21603924]
2.8e+00
3.2e+00
2.8e+00
—
—
2.2e+00
2.2e+00
cases:3.92%
controls:0.26%
cases:5.61%
controls:0.24%
cases:1.46%
controls:0.09%
—
—
—
—
cases:1.86%
controls:0.20%
cases:1.75%
controls:0.19%
35
23
857
8897
50
21
842
8899
13
8
879
8912
—
—
16
17
842
8443
8
9
449
4658
desloratadine; oral
R06AX27 [21603526]
1.8e+00
2.3e+00
2.6e+00
—
2.4e+00
2.2e+00
2.0e+00
cases:36.55%
controls:9.05%
cases:33.41%
controls:4.81%
cases:10.65%
controls:0.87%
—
—
cases:9.42%
controls:0.92%
cases:31.12%
controls:4.99%
cases:41.79%
controls:8.61%
326
807
566
8113
298
429
594
8491
95
78
797
8842
—
84
82
808
8809
267
422
591
8038
191
402
266
4265
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
1.9e+00
2.7e+00
3.5e+00
—
1.6e+00
2.6e+00
2.4e+00
cases:22.98%
controls:4.17%
cases:15.36%
controls:1.22%
cases:1.79%
controls:0.06%
—
—
cases:0.56%
controls:0.11%
cases:13.87%
controls:1.16%
cases:26.04%
controls:3.02%
205
372
687
8548
137
109
755
8811
16
5
876
8915
—
5
10
887
8881
119
98
739
8362
119
141
338
4526
Subcutaneous
ZX112 [2001311492]
4.0e+00
5.3e+00
—
1.0e+50
—
3.6e+00
—
cases:8.07%
controls:0.17%
cases:12.33%
controls:0.07%
—
—
cases:1.46%
controls:0.00%
—
—
cases:2.10%
controls:0.06%
—
—
72
15
820
8905
110
6
782
8914
—
13
0
879
8920
—
18
5
840
8455
—
Otolaryngology
4 [38004449]
1.9e+00
2.3e+00
2.6e+00
—
2.7e+00
2.0e+00
1.3e+00
cases:45.29%
controls:11.49%
cases:30.27%
controls:4.16%
cases:8.18%
controls:0.65%
—
—
cases:6.73%
controls:0.47%
cases:23.08%
controls:4.05%
cases:32.60%
controls:11.61%
404
1025
488
7895
270
371
622
8549
73
58
819
8862
—
60
42
832
8849
198
343
660
8117
149
542
308
4125
epinephrine
S01EA01 [21603673]
2.3e+00
2.8e+00
—
1.0e+50
2.4e+00
2.6e+00
2.5e+00
cases:13.23%
controls:1.54%
cases:10.54%
controls:0.72%
—
—
cases:0.56%
controls:0.00%
cases:0.90%
controls:0.08%
cases:7.11%
controls:0.59%
cases:14.88%
controls:1.35%
118
137
774
8783
94
64
798
8856
—
5
0
887
8920
8
7
884
8884
61
50
797
8410
68
63
389
4604
epinephrine; parenteral
C01CA24 [21600303]
2.3e+00
2.8e+00
—
1.0e+50
2.4e+00
2.6e+00
2.5e+00
cases:13.23%
controls:1.54%
cases:10.54%
controls:0.72%
—
—
cases:0.56%
controls:0.00%
cases:0.90%
controls:0.08%
cases:7.11%
controls:0.59%
cases:14.88%
controls:1.35%
118
137
774
8783
94
64
798
8856
—
5
0
887
8920
8
7
884
8884
61
50
797
8410
68
63
389
4604
Basophils [#/volume] in Blood
26444-0 [3006315]
2.0e+00
3.1e+00
1.6e+00
1.9e+00
1.3e+00
2.4e+00
2.2e+00
cases:71.97%
controls:26.14%
cases:77.91%
controls:13.81%
cases:11.55%
controls:2.53%
cases:0.67%
controls:0.10%
cases:9.08%
controls:2.69%
cases:63.52%
controls:13.50%
cases:77.46%
controls:27.21%
642
2332
250
6588
695
1232
197
7688
103
226
789
8694
6
9
886
8911
81
239
811
8652
545
1142
313
7318
354
1270
103
3397
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.0e+00
3.1e+00
1.6e+00
1.9e+00
1.3e+00
2.4e+00
2.2e+00
cases:71.86%
controls:26.13%
cases:77.91%
controls:13.81%
cases:11.55%
controls:2.53%
cases:0.67%
controls:0.10%
cases:8.97%
controls:2.69%
cases:63.52%
controls:13.50%
cases:77.46%
controls:27.15%
641
2331
251
6589
695
1232
197
7688
103
226
789
8694
6
9
886
8911
80
239
812
8652
545
1142
313
7318
354
1267
103
3400
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
2.0e+00
3.1e+00
1.6e+00
1.9e+00
1.3e+00
2.4e+00
2.2e+00
cases:72.76%
controls:27.19%
cases:77.80%
controls:14.02%
cases:11.66%
controls:2.52%
cases:0.67%
controls:0.10%
cases:8.97%
controls:2.70%
cases:63.87%
controls:13.66%
cases:77.46%
controls:27.45%
649
2425
243
6495
694
1251
198
7669
104
225
788
8695
6
9
886
8911
80
240
812
8651
548
1156
310
7304
354
1281
103
3386
olodaterol and tiotropium bromide
R03AL06 [1588644]
2.8e+00
3.0e+00
—
—
—
3.2e+00
3.5e+00
cases:2.91%
controls:0.18%
cases:3.03%
controls:0.16%
—
—
—
—
—
—
cases:3.50%
controls:0.15%
cases:5.91%
controls:0.19%
26
16
866
8904
27
14
865
8906
—
—
—
30
13
828
8447
27
9
430
4658
Bacteria identified in Sputum by Culture
6460-0 [3023419]
3.0e+00
3.5e+00
—
—
—
2.8e+00
2.9e+00
cases:7.51%
controls:0.39%
cases:4.82%
controls:0.15%
—
—
—
—
—
—
cases:2.21%
controls:0.14%
cases:7.00%
controls:0.41%
67
35
825
8885
43
13
849
8907
—
—
—
19
12
839
8448
32
19
425
4648
formoterol; inhalant
R03AC13 [21603267]
2.7e+00
2.5e+00
—
1.0e+50
2.5e+00
2.5e+00
2.1e+00
cases:5.04%
controls:0.36%
cases:2.35%
controls:0.20%
—
—
cases:0.56%
controls:0.00%
cases:0.78%
controls:0.07%
cases:2.56%
controls:0.22%
cases:2.84%
controls:0.34%
45
32
847
8888
21
18
871
8902
—
5
0
887
8920
7
6
885
8885
22
19
836
8441
13
16
444
4651
Other polyp of sinus
J33.8 [45591556]
4.3e+00
4.7e+00
—
1.0e+50
—
—
3.2e+00
cases:11.88%
controls:0.19%
cases:8.07%
controls:0.08%
—
—
cases:0.90%
controls:0.00%
—
—
—
—
cases:5.69%
controls:0.24%
106
17
786
8903
72
7
820
8913
—
8
0
884
8920
—
—
26
11
431
4656
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
8.2e-01
1.6e+00
2.3e+00
1.0e+50
4.5e+00
1.9e+00
9.9e-01
cases:5.83%
controls:2.65%
cases:3.92%
controls:0.85%
cases:1.01%
controls:0.10%
cases:0.67%
controls:0.00%
cases:7.40%
controls:0.09%
cases:4.90%
controls:0.79%
cases:6.13%
controls:2.36%
52
236
840
8684
35
76
857
8844
9
9
883
8911
6
0
886
8920
66
8
826
8883
42
67
816
8393
28
110
429
4557
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.9e+00
2.8e+00
1.6e+00
1.8e+00
1.3e+00
2.3e+00
2.1e+00
cases:67.15%
controls:24.04%
cases:70.74%
controls:12.54%
cases:10.65%
controls:2.26%
cases:0.56%
controls:0.09%
cases:7.96%
controls:2.36%
cases:57.34%
controls:11.75%
cases:70.46%
controls:23.23%
599
2144
293
6776
631
1119
261
7801
95
202
797
8718
5
8
887
8912
71
210
821
8681
492
994
366
7466
322
1084
135
3583
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.9e+00
2.8e+00
1.6e+00
1.8e+00
1.3e+00
2.3e+00
2.0e+00
cases:67.15%
controls:23.99%
cases:70.63%
controls:12.51%
cases:10.65%
controls:2.26%
cases:0.56%
controls:0.09%
cases:7.96%
controls:2.36%
cases:57.34%
controls:11.76%
cases:70.24%
controls:23.53%
599
2140
293
6780
630
1116
262
7804
95
202
797
8718
5
8
887
8912
71
210
821
8681
492
995
366
7465
321
1098
136
3569
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.9e+00
2.8e+00
1.6e+00
1.8e+00
1.3e+00
2.3e+00
2.1e+00
cases:67.15%
controls:24.20%
cases:70.63%
controls:12.57%
cases:10.65%
controls:2.28%
cases:0.56%
controls:0.09%
cases:7.85%
controls:2.36%
cases:57.34%
controls:11.77%
cases:70.46%
controls:23.33%
599
2159
293
6761
630
1121
262
7799
95
203
797
8717
5
8
887
8912
70
210
822
8681
492
996
366
7464
322
1089
135
3578
Dermatographic urticaria
L50.3 [45596376]
2.6e+00
3.4e+00
—
—
1.0e+50
3.2e+00
2.7e+00
cases:2.69%
controls:0.20%
cases:4.37%
controls:0.16%
—
—
—
—
cases:1.12%
controls:0.00%
cases:3.50%
controls:0.15%
cases:3.28%
controls:0.24%
24
18
868
8902
39
14
853
8906
—
—
10
0
882
8891
30
13
828
8447
15
11
442
4656
hydroxyzine; oral, parenteral
N05BB01 [21604590]
1.8e+00
2.3e+00
2.1e+00
—
2.4e+00
1.9e+00
1.2e+00
cases:17.94%
controls:3.51%
cases:10.76%
controls:1.15%
cases:1.91%
controls:0.24%
—
—
cases:2.24%
controls:0.20%
cases:7.46%
controls:1.18%
cases:8.97%
controls:2.85%
160
313
732
8607
96
103
796
8817
17
21
875
8899
—
20
18
872
8873
64
100
794
8360
41
133
416
4534
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.8e+00
2.8e+00
1.6e+00
1.8e+00
1.3e+00
2.3e+00
2.0e+00
cases:65.36%
controls:24.52%
cases:70.29%
controls:12.74%
cases:10.65%
controls:2.34%
cases:0.56%
controls:0.09%
cases:8.07%
controls:2.38%
cases:58.62%
controls:12.08%
cases:70.46%
controls:24.15%
583
2187
309
6733
627
1136
265
7784
95
209
797
8711
5
8
887
8912
72
212
820
8679
503
1022
355
7438
322
1127
135
3540
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.8e+00
2.8e+00
1.6e+00
1.8e+00
1.2e+00
2.3e+00
2.0e+00
cases:67.71%
controls:25.28%
cases:70.63%
controls:12.93%
cases:10.65%
controls:2.32%
cases:0.56%
controls:0.09%
cases:7.85%
controls:2.40%
cases:57.58%
controls:12.19%
cases:70.68%
controls:24.32%
604
2255
288
6665
630
1153
262
7767
95
207
797
8713
5
8
887
8912
70
213
822
8678
494
1031
364
7429
323
1135
134
3532
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.6e+00
2.0e+00
2.1e+00
—
2.0e+00
2.2e+00
1.9e+00
cases:15.92%
controls:3.81%
cases:8.86%
controls:1.33%
cases:1.57%
controls:0.19%
—
—
cases:1.35%
controls:0.19%
cases:9.44%
controls:1.12%
cases:17.94%
controls:3.28%
142
340
750
8580
79
119
813
8801
14
17
878
8903
—
12
17
880
8874
81
95
777
8365
82
153
375
4514
Eosinophil cationic protein (ECP) [Mass/volume] in Serum
25638-8 [3005791]
2.5e+00
2.8e+00
—
—
—
2.9e+00
3.5e+00
cases:3.36%
controls:0.28%
cases:1.79%
controls:0.11%
—
—
—
—
—
—
cases:1.86%
controls:0.11%
cases:5.25%
controls:0.17%
30
25
862
8895
16
10
876
8910
—
—
—
16
9
842
8451
24
8
433
4659
pimecrolimus
D11AH02 [21602339]
1.9e+00
2.5e+00
—
—
2.3e+00
2.5e+00
2.3e+00
cases:8.18%
controls:1.26%
cases:4.48%
controls:0.39%
—
—
—
—
cases:0.67%
controls:0.07%
cases:3.96%
controls:0.34%
cases:9.19%
controls:1.01%
73
112
819
8808
40
35
852
8885
—
—
6
6
886
8885
34
29
824
8431
42
47
415
4620
Local dermatologic skincare
TQW80 [2001310149]
2.4e+00
3.2e+00
1.0e+50
1.0e+50
—
3.3e+00
2.6e+00
cases:4.60%
controls:0.45%
cases:3.81%
controls:0.16%
cases:0.78%
controls:0.00%
cases:0.56%
controls:0.00%
—
—
cases:1.52%
controls:0.06%
cases:2.63%
controls:0.19%
41
40
851
8880
34
14
858
8906
7
0
885
8920
5
0
887
8920
—
13
5
845
8455
12
9
445
4658
Rhinopharyngoscopy
UDH02 [2001301680]
2.9e+00
3.2e+00
—
—
—
3.0e+00
2.4e+00
cases:14.91%
controls:0.96%
cases:7.17%
controls:0.33%
—
—
—
—
—
—
cases:3.96%
controls:0.21%
cases:5.25%
controls:0.51%
133
86
759
8834
64
29
828
8891
—
—
—
34
18
824
8442
24
24
433
4643
Cone beam CT of paranasal sinus
DM1AI [2001301744]
3.5e+00
3.5e+00
—
—
—
2.0e+00
2.4e+00
cases:10.76%
controls:0.38%
cases:5.27%
controls:0.17%
—
—
—
—
—
—
cases:1.05%
controls:0.14%
cases:3.28%
controls:0.32%
96
34
796
8886
47
15
845
8905
—
—
—
9
12
849
8448
15
15
442
4652
terbutaline; inhalant
R03AC03 [21603257]
1.7e+00
1.8e+00
2.0e+00
—
2.1e+00
1.7e+00
2.0e+00
cases:10.09%
controls:2.07%
cases:6.39%
controls:1.07%
cases:1.12%
controls:0.16%
—
—
cases:1.35%
controls:0.17%
cases:4.90%
controls:0.91%
cases:7.66%
controls:1.14%
90
185
802
8735
57
95
835
8825
10
14
882
8906
—
12
15
880
8876
42
77
816
8383
35
53
422
4614
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.8e+00
2.6e+00
1.6e+00
—
1.2e+00
2.2e+00
1.8e+00
cases:54.82%
controls:17.20%
cases:56.39%
controls:8.79%
cases:7.85%
controls:1.72%
—
—
cases:5.38%
controls:1.65%
cases:45.34%
controls:8.38%
cases:52.95%
controls:15.04%
489
1534
403
7386
503
784
389
8136
70
153
822
8767
—
48
147
844
8744
389
709
469
7751
242
702
215
3965
fluticasone furoate; nasal
R01AD12 [21605053]
1.9e+00
2.0e+00
2.1e+00
—
2.1e+00
1.8e+00
1.4e+00
cases:52.24%
controls:14.51%
cases:32.62%
controls:6.01%
cases:8.07%
controls:1.10%
—
—
cases:8.18%
controls:1.06%
cases:25.99%
controls:5.67%
cases:33.48%
controls:11.53%
466
1294
426
7626
291
536
601
8384
72
98
820
8822
—
73
94
819
8797
223
480
635
7980
153
538
304
4129
fluticasone; nasal
R01AD08 [21605050]
1.9e+00
2.0e+00
2.1e+00
—
2.1e+00
1.8e+00
1.4e+00
cases:52.24%
controls:14.51%
cases:32.62%
controls:6.01%
cases:8.07%
controls:1.10%
—
—
cases:8.18%
controls:1.06%
cases:25.99%
controls:5.67%
cases:33.48%
controls:11.53%
466
1294
426
7626
291
536
601
8384
72
98
820
8822
—
73
94
819
8797
223
480
635
7980
153
538
304
4129
cromoglicic acid
S01GX01 [21605085]
1.2e+00
1.7e+00
2.1e+00
—
2.6e+00
1.9e+00
1.6e+00
cases:12.78%
controls:4.42%
cases:7.06%
controls:1.36%
cases:1.79%
controls:0.21%
—
—
cases:2.47%
controls:0.18%
cases:9.79%
controls:1.52%
cases:14.66%
controls:3.39%
114
394
778
8526
63
121
829
8799
16
19
876
8901
—
22
16
870
8875
84
129
774
8331
67
158
390
4509
salmeterol and fluticasone
R03AK06 [21603280]
2.1e+00
1.9e+00
2.1e+00
1.0e+50
1.8e+00
1.6e+00
1.5e+00
cases:19.28%
controls:2.80%
cases:10.43%
controls:1.65%
cases:3.03%
controls:0.38%
cases:1.23%
controls:0.00%
cases:2.69%
controls:0.47%
cases:7.58%
controls:1.57%
cases:10.50%
controls:2.49%
172
250
720
8670
93
147
799
8773
27
34
865
8886
11
0
881
8920
24
42
868
8849
65
133
793
8327
48
116
409
4551
hydrocortisone; local oral
A01AC03 [21600036]
2.0e+00
2.8e+00
2.4e+00
—
—
2.3e+00
1.4e+00
cases:10.09%
controls:1.46%
cases:6.17%
controls:0.41%
cases:0.90%
controls:0.08%
—
—
—
—
cases:3.73%
controls:0.39%
cases:6.35%
controls:1.61%
90
130
802
8790
55
37
837
8883
8
7
884
8913
—
—
32
33
826
8427
29
75
428
4592
salbutamol; inhalant
R03AC02 [21603256]
2.0e+00
2.0e+00
1.8e+00
—
1.7e+00
1.8e+00
1.7e+00
cases:66.93%
controls:21.76%
cases:46.19%
controls:10.78%
cases:8.63%
controls:1.61%
—
—
cases:8.07%
controls:1.51%
cases:41.14%
controls:10.57%
cases:61.05%
controls:21.94%
597
1941
295
6979
412
962
480
7958
77
144
815
8776
—
72
134
820
8757
353
894
505
7566
279
1024
178
3643
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.7e+00
2.8e+00
1.2e+00
1.5e+00
9.3e-01
2.2e+00
2.1e+00
cases:71.41%
controls:30.53%
cases:76.12%
controls:16.69%
cases:11.32%
controls:3.73%
cases:0.56%
controls:0.12%
cases:9.19%
controls:3.82%
cases:61.19%
controls:15.41%
cases:76.15%
controls:28.50%
637
2723
255
6197
679
1489
213
7431
101
333
791
8587
5
11
887
8909
82
340
810
8551
525
1304
333
7156
348
1330
109
3337
Tryptase [Mass/volume] in Serum or Plasma
21582-2 [3019420]
2.3e+00
3.3e+00
—
—
—
2.6e+00
2.7e+00
cases:2.91%
controls:0.30%
cases:2.69%
controls:0.10%
—
—
—
—
—
—
cases:0.93%
controls:0.07%
cases:2.41%
controls:0.17%
26
27
866
8893
24
9
868
8911
—
—
—
8
6
850
8454
11
8
446
4659
Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
14277-8 [3004383]
1.8e+00
3.5e+00
—
—
—
3.1e+00
2.2e+00
cases:4.82%
controls:0.80%
cases:5.49%
controls:0.17%
—
—
—
—
—
—
cases:2.21%
controls:0.11%
cases:2.19%
controls:0.24%
43
71
849
8849
49
15
843
8905
—
—
—
19
9
839
8451
10
11
447
4656
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
2.0e+00
3.2e+00
—
—
—
2.9e+00
2.5e+00
cases:11.55%
controls:1.66%
cases:8.52%
controls:0.37%
—
—
—
—
—
—
cases:3.85%
controls:0.21%
cases:7.00%
controls:0.64%
103
148
789
8772
76
33
816
8887
—
—
—
33
18
825
8442
32
30
425
4637
Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence
14278-6 [3003284]
1.8e+00
3.5e+00
—
—
—
3.1e+00
2.2e+00
cases:4.60%
controls:0.77%
cases:5.49%
controls:0.17%
—
—
—
—
—
—
cases:2.33%
controls:0.11%
cases:2.19%
controls:0.26%
41
69
851
8851
49
15
843
8905
—
—
—
20
9
838
8451
10
12
447
4655
Allergic rhinitis due to pollen
J30.10 [2000502594]
2.1e+00
2.3e+00
—
—
2.6e+00
1.9e+00
1.7e+00
cases:8.97%
controls:1.14%
cases:4.93%
controls:0.49%
—
—
—
—
cases:1.01%
controls:0.08%
cases:3.50%
controls:0.54%
cases:6.56%
controls:1.33%
80
102
812
8818
44
44
848
8876
—
—
9
7
883
8884
30
46
828
8414
30
62
427
4605
hydrocortisone
S02BA01 [21605166]
1.4e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:23.77%
controls:7.43%
cases:16.26%
controls:2.03%
cases:2.02%
controls:0.31%
—
—
cases:1.91%
controls:0.20%
cases:10.84%
controls:2.32%
cases:18.16%
controls:6.96%
212
663
680
8257
145
181
747
8739
18
28
874
8892
—
17
18
875
8873
93
196
765
8264
83
325
374
4342
mometasone
D07AC13 [21602132]
1.5e+00
2.0e+00
2.1e+00
—
2.3e+00
1.6e+00
1.0e+00
cases:18.83%
controls:5.03%
cases:10.65%
controls:1.63%
cases:1.68%
controls:0.21%
—
—
cases:1.79%
controls:0.18%
cases:6.06%
controls:1.29%
cases:9.19%
controls:3.60%
168
449
724
8471
95
145
797
8775
15
19
877
8901
—
16
16
876
8875
52
109
806
8351
42
168
415
4499
hydrocortisone aceponate
D07AC16 [21602135]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
hydrocortisone butyrate
D07AB02 [21602106]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
hydrocortisone buteprate
D07AB11 [21602115]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
hydrocortisone
C05AA01 [21601608]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
hydrocortisone
A07EA02 [21600654]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
hydrocortisone
D07AA02 [21602102]
1.3e+00
2.2e+00
1.9e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:26.35%
controls:8.59%
cases:17.83%
controls:2.44%
cases:2.24%
controls:0.36%
—
—
cases:2.35%
controls:0.24%
cases:12.59%
controls:2.75%
cases:20.79%
controls:7.84%
235
766
657
8154
159
218
733
8702
20
32
872
8888
—
21
21
871
8870
108
233
750
8227
95
366
362
4301
fenoterol and ipratropium bromide
R03AL01 [43534843]
2.4e+00
2.7e+00
—
—
—
2.7e+00
2.6e+00
cases:4.04%
controls:0.39%
cases:2.80%
controls:0.19%
—
—
—
—
—
—
cases:2.80%
controls:0.20%
cases:5.47%
controls:0.41%
36
35
856
8885
25
17
867
8903
—
—
—
24
17
834
8443
25
19
432
4648
umeclidinium bromide; inhalant
R03BB07 [45893265]
2.1e+00
2.9e+00
—
—
—
2.7e+00
2.6e+00
cases:1.23%
controls:0.16%
cases:1.68%
controls:0.09%
—
—
—
—
—
—
cases:1.05%
controls:0.07%
cases:1.75%
controls:0.13%
11
14
881
8906
15
8
877
8912
—
—
—
9
6
849
8454
8
6
449
4661
Myeloperoxidase Ab [Units/volume] in Serum
6969-0 [3023150]
2.2e+00
3.0e+00
—
—
—
3.3e+00
1.8e+00
cases:4.60%
controls:0.55%
cases:3.03%
controls:0.16%
—
—
—
—
—
—
cases:1.98%
controls:0.07%
cases:2.84%
controls:0.47%
41
49
851
8871
27
14
865
8906
—
—
—
17
6
841
8454
13
22
444
4645
betamethasone
A07EA04 [21600656]
1.5e+00
1.9e+00
2.2e+00
1.0e+50
2.2e+00
1.3e+00
1.2e+00
cases:29.71%
controls:8.96%
cases:18.95%
controls:3.40%
cases:3.59%
controls:0.41%
cases:1.23%
controls:0.00%
cases:3.92%
controls:0.45%
cases:12.94%
controls:3.76%
cases:24.51%
controls:8.96%
265
799
627
8121
169
303
723
8617
32
37
860
8883
11
0
881
8920
35
40
857
8851
111
318
747
8142
112
418
345
4249
betamethasone
S02BA07 [21605169]
1.5e+00
1.9e+00
2.2e+00
1.0e+50
2.2e+00
1.3e+00
1.2e+00
cases:29.71%
controls:8.96%
cases:18.95%
controls:3.40%
cases:3.59%
controls:0.41%
cases:1.23%
controls:0.00%
cases:3.92%
controls:0.45%
cases:12.94%
controls:3.76%
cases:24.51%
controls:8.96%
265
799
627
8121
169
303
723
8617
32
37
860
8883
11
0
881
8920
35
40
857
8851
111
318
747
8142
112
418
345
4249
betamethasone
D07AC01 [21602120]
1.5e+00
1.9e+00
2.2e+00
1.0e+50
2.2e+00
1.3e+00
1.2e+00
cases:29.71%
controls:8.96%
cases:18.95%
controls:3.40%
cases:3.59%
controls:0.41%
cases:1.23%
controls:0.00%
cases:3.92%
controls:0.45%
cases:12.94%
controls:3.76%
cases:24.51%
controls:8.96%
265
799
627
8121
169
303
723
8617
32
37
860
8883
11
0
881
8920
35
40
857
8851
111
318
747
8142
112
418
345
4249
betamethasone
C05AA05 [21601610]
1.5e+00
1.9e+00
2.2e+00
1.0e+50
2.2e+00
1.3e+00
1.2e+00
cases:29.71%
controls:8.96%
cases:18.95%
controls:3.40%
cases:3.59%
controls:0.41%
cases:1.23%
controls:0.00%
cases:3.92%
controls:0.45%
cases:12.94%
controls:3.76%
cases:24.51%
controls:8.96%
265
799
627
8121
169
303
723
8617
32
37
860
8883
11
0
881
8920
35
40
857
8851
111
318
747
8142
112
418
345
4249
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.4e+00
2.0e+00
1.8e+00
—
1.4e+00
1.9e+00
1.7e+00
cases:9.19%
controls:2.52%
cases:15.13%
controls:2.31%
cases:2.24%
controls:0.37%
—
—
cases:1.91%
controls:0.49%
cases:12.82%
controls:2.21%
cases:24.95%
controls:5.51%
82
225
810
8695
135
206
757
8714
20
33
872
8887
—
17
44
875
8847
110
187
748
8273
114
257
343
4410
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.4e+00
2.0e+00
1.8e+00
—
1.4e+00
1.8e+00
1.7e+00
cases:9.75%
controls:2.65%
cases:14.69%
controls:2.23%
cases:2.02%
controls:0.34%
—
—
cases:1.79%
controls:0.45%
cases:11.54%
controls:2.09%
cases:23.85%
controls:5.23%
87
236
805
8684
131
199
761
8721
18
30
874
8890
—
16
40
876
8851
99
177
759
8283
109
244
348
4423
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.4e+00
2.0e+00
1.7e+00
—
1.4e+00
1.8e+00
1.8e+00
cases:9.08%
controls:2.48%
cases:14.13%
controls:2.12%
cases:1.79%
controls:0.33%
—
—
cases:1.79%
controls:0.45%
cases:10.96%
controls:2.01%
cases:24.29%
controls:5.14%
81
221
811
8699
126
189
766
8731
16
29
876
8891
—
16
40
876
8851
94
170
764
8290
111
240
346
4427
UVB narrow spectrum light therapy
WXQ27 [2001310161]
3.7e+00
4.0e+00
—
—
—
—
2.3e+00
cases:5.61%
controls:0.15%
cases:3.03%
controls:0.06%
—
—
—
—
—
—
—
—
cases:1.09%
controls:0.11%
50
13
842
8907
27
5
865
8915
—
—
—
—
5
5
452
4662
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.3e+00
2.0e+00
1.8e+00
—
1.3e+00
1.8e+00
1.7e+00
cases:9.87%
controls:2.80%
cases:14.80%
controls:2.29%
cases:2.02%
controls:0.34%
—
—
cases:1.79%
controls:0.47%
cases:11.54%
controls:2.12%
cases:24.29%
controls:5.36%
88
250
804
8670
132
204
760
8716
18
30
874
8890
—
16
42
876
8849
99
179
759
8281
111
250
346
4417
Sinoscopy
UDM02 [2001301774]
3.4e+00
4.0e+00
—
—
—
2.6e+00
1.9e+00
cases:5.72%
controls:0.20%
cases:3.03%
controls:0.06%
—
—
—
—
—
—
cases:1.40%
controls:0.11%
cases:1.09%
controls:0.17%
51
18
841
8902
27
5
865
8915
—
—
—
12
9
846
8451
5
8
452
4659
High resolution CT examination of lungs
GD1DD [2001303632]
2.2e+00
3.4e+00
—
—
—
2.4e+00
2.1e+00
cases:5.16%
controls:0.63%
cases:5.04%
controls:0.18%
—
—
—
—
—
—
cases:1.86%
controls:0.18%
cases:3.72%
controls:0.47%
46
56
846
8864
45
16
847
8904
—
—
—
16
15
842
8445
17
22
440
4645
ebastine; oral
R06AX22 [21603521]
1.5e+00
1.9e+00
2.0e+00
—
1.7e+00
1.4e+00
1.4e+00
cases:11.55%
controls:2.76%
cases:10.09%
controls:1.70%
cases:2.13%
controls:0.29%
—
—
cases:1.79%
controls:0.33%
cases:7.46%
controls:1.90%
cases:8.97%
controls:2.29%
103
246
789
8674
90
152
802
8768
19
26
873
8894
—
16
29
876
8862
64
161
794
8299
41
107
416
4560
Chronic mucoid otitis media
H65.3 [45567124]
4.0e+00
—
—
—
1.0e+50
2.8e+00
3.1e+00
cases:4.04%
controls:0.08%
—
—
—
—
—
—
cases:0.90%
controls:0.00%
cases:0.93%
controls:0.06%
cases:2.84%
controls:0.13%
36
7
856
8913
—
—
—
8
0
884
8891
8
5
850
8455
13
6
444
4661
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.3e+00
2.1e+00
1.7e+00
—
1.4e+00
1.7e+00
1.5e+00
cases:31.28%
controls:11.33%
cases:31.73%
controls:5.43%
cases:4.26%
controls:0.80%
—
—
cases:3.70%
controls:0.92%
cases:23.43%
controls:5.09%
cases:38.51%
controls:12.45%
279
1011
613
7909
283
484
609
8436
38
71
854
8849
—
33
82
859
8809
201
431
657
8029
176
581
281
4086
azelastine; nasal
R01AC03 [21605035]
1.3e+00
1.6e+00
2.0e+00
—
1.7e+00
1.6e+00
1.4e+00
cases:32.29%
controls:11.11%
cases:19.17%
controls:4.52%
cases:4.71%
controls:0.66%
—
—
cases:3.81%
controls:0.73%
cases:19.58%
controls:4.69%
cases:30.63%
controls:9.64%
288
991
604
7929
171
403
721
8517
42
59
850
8861
—
34
65
858
8826
168
397
690
8063
140
450
317
4217
fluticasone, combinations
R01AD58 [43534837]
1.3e+00
1.6e+00
2.0e+00
—
1.7e+00
1.6e+00
1.4e+00
cases:32.29%
controls:11.11%
cases:19.17%
controls:4.52%
cases:4.71%
controls:0.66%
—
—
cases:3.81%
controls:0.73%
cases:19.58%
controls:4.68%
cases:30.42%
controls:9.64%
288
991
604
7929
171
403
721
8517
42
59
850
8861
—
34
65
858
8826
168
396
690
8064
139
450
318
4217
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.1e+00
1.7e+00
1.1e+00
1.9e+00
8.5e-01
1.5e+00
1.4e+00
cases:47.98%
controls:23.05%
cases:53.03%
controls:16.76%
cases:10.31%
controls:3.52%
cases:0.90%
controls:0.13%
cases:8.18%
controls:3.67%
cases:47.20%
controls:16.89%
cases:62.58%
controls:30.04%
428
2056
464
6864
473
1495
419
7425
92
314
800
8606
8
12
884
8908
73
326
819
8565
405
1429
453
7031
286
1402
171
3265
Spirometry
127783003 [4133840]
2.5e+00
3.9e+00
—
—
—
3.1e+00
—
cases:7.96%
controls:0.70%
cases:3.92%
controls:0.08%
—
—
—
—
—
—
cases:1.52%
controls:0.07%
—
—
71
62
821
8858
35
7
857
8913
—
—
—
13
6
845
8454
—
carbamide
D02AE01 [21601975]
2.1e+00
2.3e+00
—
—
—
2.8e+00
2.3e+00
cases:8.52%
controls:1.09%
cases:1.68%
controls:0.18%
—
—
—
—
—
—
cases:1.28%
controls:0.08%
cases:1.09%
controls:0.11%
76
97
816
8823
15
16
877
8904
—
—
—
11
7
847
8453
5
5
452
4662
Dermatological photography
XQ848 [2001310110]
1.7e+00
3.3e+00
1.0e+50
—
—
2.6e+00
1.9e+00
cases:2.80%
controls:0.55%
cases:3.59%
controls:0.13%
cases:0.56%
controls:0.00%
—
—
—
—
cases:2.10%
controls:0.17%
cases:2.41%
controls:0.36%
25
49
867
8871
32
12
860
8908
5
0
887
8920
—
—
18
14
840
8446
11
17
446
4650
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
2.0e+00
2.9e+00
—
—
—
2.4e+00
2.1e+00
cases:11.43%
controls:1.77%
cases:7.96%
controls:0.47%
—
—
—
—
—
—
cases:4.08%
controls:0.39%
cases:9.63%
controls:1.33%
102
158
790
8762
71
42
821
8878
—
—
—
35
33
823
8427
44
62
413
4605
budesonide; inhalant
R03BA02 [21603285]
1.7e+00
1.5e+00
1.7e+00
—
1.7e+00
1.3e+00
1.3e+00
cases:26.68%
controls:6.05%
cases:13.23%
controls:3.28%
cases:3.36%
controls:0.65%
—
—
cases:3.48%
controls:0.64%
cases:10.72%
controls:3.06%
cases:15.32%
controls:4.67%
238
540
654
8380
118
293
774
8627
30
58
862
8862
—
31
57
861
8834
92
259
766
8201
70
218
387
4449
desonide
D07AB08 [21602112]
1.7e+00
2.4e+00
1.9e+00
—
—
1.8e+00
1.4e+00
cases:13.68%
controls:2.78%
cases:6.95%
controls:0.68%
cases:1.01%
controls:0.15%
—
—
—
—
cases:4.55%
controls:0.78%
cases:7.44%
controls:1.91%
122
248
770
8672
62
61
830
8859
9
13
883
8907
—
—
39
66
819
8394
34
89
423
4578
clobetasol
D07AD01 [21602141]
1.3e+00
1.6e+00
2.3e+00
—
2.0e+00
1.1e+00
8.9e-01
cases:12.44%
controls:3.91%
cases:8.86%
controls:1.85%
cases:1.57%
controls:0.16%
—
—
cases:1.68%
controls:0.24%
cases:5.83%
controls:1.99%
cases:11.38%
controls:4.99%
111
349
781
8571
79
165
813
8755
14
14
878
8906
—
15
21
877
8870
50
168
808
8292
52
233
405
4434
other preparations, combinations; ointment
C05AX03 [21601631]
1.2e+00
1.7e+00
2.3e+00
—
1.9e+00
1.0e+00
9.6e-01
cases:9.64%
controls:3.06%
cases:4.37%
controls:0.80%
cases:0.78%
controls:0.08%
—
—
cases:0.78%
controls:0.12%
cases:2.45%
controls:0.90%
cases:6.13%
controls:2.44%
86
273
806
8647
39
71
853
8849
7
7
885
8913
—
7
11
885
8880
21
76
837
8384
28
114
429
4553
Hypersensitivity skin testing
268377001 [4147813]
2.2e+00
2.7e+00
—
—
—
2.4e+00
1.9e+00
cases:7.40%
controls:0.90%
cases:3.14%
controls:0.22%
—
—
—
—
—
—
cases:1.86%
controls:0.18%
cases:2.84%
controls:0.45%
66
80
826
8840
28
20
864
8900
—
—
—
16
15
842
8445
13
21
444
4646
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.6e+00
1.9e+00
1.5e+00
—
2.5e+00
1.6e+00
1.3e+00
cases:18.61%
controls:4.44%
cases:7.96%
controls:1.22%
cases:0.78%
controls:0.17%
—
—
cases:1.12%
controls:0.09%
cases:4.78%
controls:0.99%
cases:10.72%
controls:3.02%
166
396
726
8524
71
109
821
8811
7
15
885
8905
—
10
8
882
8883
41
84
817
8376
49
141
408
4526
Nasal polyp, unspecified
J33.9 [45567263]
3.7e+00
—
—
—
—
2.9e+00
2.5e+00
cases:4.15%
controls:0.11%
—
—
—
—
—
—
—
—
cases:1.63%
controls:0.09%
cases:1.97%
controls:0.17%
37
10
855
8910
—
—
—
—
14
8
844
8452
9
8
448
4659
Laboratory Visit
OMOP4822461 [32036]
1.1e+00
2.1e+00
6.4e-01
1.1e+00
5.3e-01
1.5e+00
2.0e+00
cases:97.76%
controls:93.68%
cases:96.64%
controls:78.46%
cases:35.31%
controls:22.29%
cases:2.91%
controls:1.00%
cases:32.96%
controls:22.48%
cases:94.29%
controls:77.84%
cases:99.34%
controls:95.33%
872
8356
20
564
862
6999
30
1921
315
1988
577
6932
26
89
866
8831
294
1999
598
6892
809
6585
49
1875
454
4449
3
218
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
2.1e+00
2.6e+00
—
—
—
2.3e+00
1.9e+00
cases:6.28%
controls:0.83%
cases:3.03%
controls:0.22%
—
—
—
—
—
—
cases:1.75%
controls:0.18%
cases:3.72%
controls:0.56%
56
74
836
8846
27
20
865
8900
—
—
—
15
15
843
8445
17
26
440
4641
ipratropium bromide; inhalant
R03BB01 [21603293]
2.2e+00
2.2e+00
—
—
—
2.4e+00
2.1e+00
cases:3.59%
controls:0.40%
cases:1.46%
controls:0.16%
—
—
—
—
—
—
cases:1.52%
controls:0.14%
cases:3.50%
controls:0.45%
32
36
860
8884
13
14
879
8906
—
—
—
13
12
845
8448
16
21
441
4646
Platelets [#/volume] in Blood
26515-7 [3007461]
1.3e+00
2.2e+00
6.5e-01
1.1e+00
4.9e-01
1.5e+00
1.7e+00
cases:95.29%
controls:85.26%
cases:93.16%
controls:60.52%
cases:21.08%
controls:12.24%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.56%
cases:86.95%
controls:60.46%
cases:97.81%
controls:88.88%
850
7605
42
1315
831
5398
61
3522
188
1092
704
7828
14
45
878
8875
169
1117
723
7774
746
5115
112
3345
447
4148
10
519
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.3e+00
2.2e+00
6.5e-01
1.1e+00
4.9e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.48%
cases:93.16%
controls:60.61%
cases:21.08%
controls:12.25%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.54%
cases:86.83%
controls:60.52%
cases:97.81%
controls:88.88%
851
7625
41
1295
831
5406
61
3514
188
1093
704
7827
14
45
878
8875
169
1115
723
7776
745
5120
113
3340
447
4148
10
519
MCH [Entitic mass]
28539-5 [3035941]
1.3e+00
2.2e+00
6.4e-01
1.1e+00
4.9e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.41%
cases:93.16%
controls:60.56%
cases:20.96%
controls:12.25%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.54%
cases:86.83%
controls:60.54%
cases:97.81%
controls:88.97%
851
7619
41
1301
831
5402
61
3518
187
1093
705
7827
14
45
878
8875
169
1115
723
7776
745
5122
113
3338
447
4152
10
515
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.3e+00
2.2e+00
6.4e-01
1.1e+00
4.8e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.52%
cases:93.16%
controls:60.62%
cases:21.08%
controls:12.30%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.61%
cases:86.95%
controls:60.57%
cases:97.81%
controls:89.03%
851
7628
41
1292
831
5407
61
3513
188
1097
704
7823
14
45
878
8875
169
1121
723
7770
746
5124
112
3336
447
4155
10
512
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.3e+00
2.2e+00
6.5e-01
1.1e+00
4.8e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.54%
cases:93.16%
controls:60.67%
cases:21.08%
controls:12.26%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.60%
cases:86.95%
controls:60.59%
cases:97.81%
controls:89.03%
851
7630
41
1290
831
5412
61
3508
188
1094
704
7826
14
45
878
8875
169
1120
723
7771
746
5126
112
3334
447
4155
10
512
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.3e+00
2.2e+00
6.5e-01
1.1e+00
4.8e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.59%
cases:93.16%
controls:60.66%
cases:21.08%
controls:12.26%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.62%
cases:86.95%
controls:60.65%
cases:97.81%
controls:88.97%
851
7635
41
1285
831
5411
61
3509
188
1094
704
7826
14
45
878
8875
169
1122
723
7769
746
5131
112
3329
447
4152
10
515
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.2e+00
2.2e+00
6.4e-01
1.1e+00
4.8e-01
1.5e+00
1.7e+00
cases:95.40%
controls:85.61%
cases:93.16%
controls:60.71%
cases:21.08%
controls:12.30%
cases:1.57%
controls:0.50%
cases:18.95%
controls:12.62%
cases:86.95%
controls:60.61%
cases:97.81%
controls:88.99%
851
7636
41
1284
831
5415
61
3505
188
1097
704
7823
14
45
878
8875
169
1122
723
7769
746
5128
112
3332
447
4153
10
514
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
1.8e+00
2.9e+00
—
—
—
2.1e+00
2.1e+00
cases:7.40%
controls:1.29%
cases:5.38%
controls:0.33%
—
—
—
—
—
—
cases:2.45%
controls:0.31%
cases:6.56%
controls:0.86%
66
115
826
8805
48
29
844
8891
—
—
—
21
26
837
8434
30
40
427
4627
cetirizine; oral
R06AE07 [21603497]
1.4e+00
1.7e+00
1.6e+00
—
1.5e+00
1.3e+00
1.1e+00
cases:30.38%
controls:9.74%
cases:22.65%
controls:4.94%
cases:4.15%
controls:0.86%
—
—
cases:4.04%
controls:0.93%
cases:16.08%
controls:4.80%
cases:21.88%
controls:8.29%
271
869
621
8051
202
441
690
8479
37
77
855
8843
—
36
83
856
8808
138
406
720
8054
100
387
357
4280
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
1.2e+00
2.5e+00
—
—
—
2.5e+00
2.3e+00
cases:1.46%
controls:0.44%
cases:1.23%
controls:0.10%
—
—
—
—
—
—
cases:1.17%
controls:0.09%
cases:1.75%
controls:0.17%
13
39
879
8881
11
9
881
8911
—
—
—
10
8
848
8452
8
8
449
4659
Puncture of maxillary antrum
TDM10 [2001301819]
3.2e+00
3.3e+00
—
—
—
—
2.1e+00
cases:8.30%
controls:0.38%
cases:2.35%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.21%
74
34
818
8886
21
8
871
8912
—
—
—
—
8
10
449
4657
Diffusion capacity of lung
54715006 [4182985]
1.7e+00
2.3e+00
—
—
—
2.2e+00
2.3e+00
cases:2.24%
controls:0.40%
cases:1.35%
controls:0.13%
—
—
—
—
—
—
cases:0.93%
controls:0.11%
cases:1.97%
controls:0.19%
20
36
872
8884
12
12
880
8908
—
—
—
8
9
850
8451
9
9
448
4658
Desensitization to allergens
Z51.6 [45605134]
2.4e+00
3.3e+00
—
—
—
—
2.7e+00
cases:2.13%
controls:0.19%
cases:1.46%
controls:0.06%
—
—
—
—
—
—
—
—
cases:1.53%
controls:0.11%
19
17
873
8903
13
5
879
8915
—
—
—
—
7
5
450
4662
insulin (human); parenteral
A10AD01 [21600729]
1.2e+00
2.4e+00
—
—
—
2.5e+00
2.2e+00
cases:1.57%
controls:0.46%
cases:1.23%
controls:0.11%
—
—
—
—
—
—
cases:1.28%
controls:0.11%
cases:1.75%
controls:0.19%
14
41
878
8879
11
10
881
8910
—
—
—
11
9
847
8451
8
9
449
4658
Other allergic rhinitis
J30.3 [45538477]
1.8e+00
2.4e+00
—
—
—
2.4e+00
1.7e+00
cases:3.25%
controls:0.56%
cases:2.24%
controls:0.20%
—
—
—
—
—
—
cases:1.28%
controls:0.12%
cases:2.63%
controls:0.47%
29
50
863
8870
20
18
872
8902
—
—
—
11
10
847
8450
12
22
445
4645
betamethasone
S03BA03 [21605203]
1.5e+00
2.0e+00
2.8e+00
—
1.7e+00
1.0e+00
1.0e+00
cases:10.99%
controls:2.72%
cases:6.50%
controls:0.94%
cases:0.90%
controls:0.06%
—
—
cases:0.56%
controls:0.10%
cases:2.91%
controls:1.05%
cases:6.78%
controls:2.55%
98
243
794
8677
58
84
834
8836
8
5
884
8915
—
5
9
887
8882
25
89
833
8371
31
119
426
4548
Atopic dermatitis, unspecified
L20.9 [45548191]
1.9e+00
2.6e+00
—
—
—
2.0e+00
1.8e+00
cases:3.36%
controls:0.54%
cases:2.58%
controls:0.19%
—
—
—
—
—
—
cases:1.86%
controls:0.26%
cases:3.50%
controls:0.58%
30
48
862
8872
23
17
869
8903
—
—
—
16
22
842
8438
16
27
441
4640
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
1.7e+00
2.6e+00
—
—
—
1.8e+00
2.1e+00
cases:5.27%
controls:1.05%
cases:3.81%
controls:0.28%
—
—
—
—
—
—
cases:1.17%
controls:0.20%
cases:4.38%
controls:0.56%
47
94
845
8826
34
25
858
8895
—
—
—
10
17
848
8443
20
26
437
4641
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
1.6e+00
2.6e+00
—
—
—
1.9e+00
2.0e+00
cases:7.17%
controls:1.48%
cases:5.04%
controls:0.40%
—
—
—
—
—
—
cases:2.56%
controls:0.40%
cases:6.35%
controls:0.90%
64
132
828
8788
45
36
847
8884
—
—
—
22
34
836
8426
29
42
428
4625
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
1.6e+00
2.5e+00
—
—
—
1.9e+00
2.0e+00
cases:7.06%
controls:1.46%
cases:5.04%
controls:0.41%
—
—
—
—
—
—
cases:2.56%
controls:0.40%
cases:6.35%
controls:0.92%
63
130
829
8790
45
37
847
8883
—
—
—
22
34
836
8426
29
43
428
4624
Timothy IgE Ab [Units/volume] in Serum
6265-3 [3003888]
2.8e+00
3.8e+00
—
—
—
5.7e-01
1.4e+00
cases:13.90%
controls:0.95%
cases:10.09%
controls:0.26%
—
—
—
—
—
—
cases:0.58%
controls:0.33%
cases:3.72%
controls:0.94%
124
85
768
8835
90
23
802
8897
—
—
—
5
28
853
8432
17
44
440
4623
Mycobacterium sp identified in Specimen
40699-1 [3042631]
2.0e+00
3.0e+00
—
—
—
—
2.9e+00
cases:3.36%
controls:0.45%
cases:1.57%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.97%
controls:0.11%
30
40
862
8880
14
7
878
8913
—
—
—
—
9
5
448
4662
European house dust mite IgE Ab [Units/volume] in Serum
6096-2 [3023351]
2.7e+00
3.9e+00
—
—
—
1.3e+00
1.3e+00
cases:14.46%
controls:1.09%
cases:12.11%
controls:0.27%
—
—
—
—
—
—
cases:1.17%
controls:0.33%
cases:3.94%
controls:1.09%
129
97
763
8823
108
24
784
8896
—
—
—
10
28
848
8432
18
51
439
4616
azithromycin; oral, parenteral
J01FA10 [21602978]
1.3e+00
1.9e+00
2.0e+00
—
1.6e+00
1.5e+00
1.2e+00
cases:20.29%
controls:6.23%
cases:7.51%
controls:1.26%
cases:1.12%
controls:0.15%
—
—
cases:0.90%
controls:0.19%
cases:5.59%
controls:1.26%
cases:11.82%
controls:4.05%
181
556
711
8364
67
112
825
8808
10
13
882
8907
—
8
17
884
8874
48
107
810
8353
54
189
403
4478
erdosteine; oral
R05CB15 [21603394]
1.7e+00
1.8e+00
1.9e+00
—
—
1.2e+00
1.3e+00
cases:21.08%
controls:4.54%
cases:9.75%
controls:1.80%
cases:1.46%
controls:0.21%
—
—
—
—
cases:6.53%
controls:2.04%
cases:21.44%
controls:7.01%
188
405
704
8515
87
161
805
8759
13
19
879
8901
—
—
56
173
802
8287
98
327
359
4340
Horse dander IgE Ab [Units/volume] in Serum
6143-2 [3010726]
2.8e+00
3.8e+00
—
—
—
8.7e-01
1.3e+00
cases:13.00%
controls:0.94%
cases:10.09%
controls:0.25%
—
—
—
—
—
—
cases:0.70%
controls:0.30%
cases:3.50%
controls:0.94%
116
84
776
8836
90
22
802
8898
—
—
—
6
25
852
8435
16
44
441
4623
Immunoglobulin typing, IgG
1712009 [4062490]
2.5e+00
3.1e+00
—
—
—
—
2.3e+00
cases:5.27%
controls:0.45%
cases:2.35%
controls:0.11%
—
—
—
—
—
—
—
—
cases:3.06%
controls:0.32%
47
40
845
8880
21
10
871
8910
—
—
—
—
14
15
443
4652
Mugwort IgE Ab [Units/volume] in Serum
6183-8 [3008401]
2.7e+00
3.7e+00
—
—
—
—
1.4e+00
cases:12.00%
controls:0.91%
cases:9.87%
controls:0.26%
—
—
—
—
—
—
—
—
cases:3.50%
controls:0.92%
107
81
785
8839
88
23
804
8897
—
—
—
—
16
43
441
4624
Chronic serous otitis media
H65.2 [45581726]
2.5e+00
2.5e+00
—
—
—
2.8e+00
—
cases:1.35%
controls:0.11%
cases:1.23%
controls:0.10%
—
—
—
—
—
—
cases:1.52%
controls:0.09%
—
—
12
10
880
8910
11
9
881
8911
—
—
—
13
8
845
8452
—
Topical pimecrolimus and tacrolimus
317 [2001600278]
4.0e+00
—
—
—
—
—
3.8e+00
cases:7.62%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.11%
68
13
824
8907
—
—
—
—
—
20
5
437
4662
Cat dander IgE Ab [Units/volume] in Serum
6833-8 [3023430]
2.6e+00
3.7e+00
—
—
—
7.7e-01
1.4e+00
cases:8.63%
controls:0.72%
cases:8.30%
controls:0.21%
—
—
—
—
—
—
cases:0.58%
controls:0.27%
cases:3.50%
controls:0.86%
77
64
815
8856
74
19
818
8901
—
—
—
5
23
853
8437
16
40
441
4627
IgG subclass 1 [Mass/volume] in Serum
2466-1 [3027135]
2.5e+00
3.0e+00
—
—
—
—
2.2e+00
cases:5.27%
controls:0.44%
cases:2.35%
controls:0.12%
—
—
—
—
—
—
—
—
cases:3.06%
controls:0.34%
47
39
845
8881
21
11
871
8909
—
—
—
—
14
16
443
4651
IgG subclass 3 [Mass/volume] in Serum
2468-7 [3024139]
2.5e+00
3.0e+00
—
—
—
—
2.2e+00
cases:5.27%
controls:0.44%
cases:2.35%
controls:0.12%
—
—
—
—
—
—
—
—
cases:3.06%
controls:0.34%
47
39
845
8881
21
11
871
8909
—
—
—
—
14
16
443
4651
IgG subclass 2 [Mass/volume] in Serum
2467-9 [3028192]
2.5e+00
3.0e+00
—
—
—
—
2.2e+00
cases:5.27%
controls:0.44%
cases:2.35%
controls:0.12%
—
—
—
—
—
—
—
—
cases:3.06%
controls:0.34%
47
39
845
8881
21
11
871
8909
—
—
—
—
14
16
443
4651
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
9.1e-01
1.2e+00
2.3e+00
—
2.2e+00
1.2e+00
4.0e-01
cases:2.91%
controls:1.19%
cases:2.13%
controls:0.67%
cases:0.90%
controls:0.09%
—
—
cases:0.78%
controls:0.09%
cases:2.10%
controls:0.67%
cases:2.63%
controls:1.78%
26
106
866
8814
19
60
873
8860
8
8
884
8912
—
7
8
885
8883
18
57
840
8403
12
83
445
4584
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.7e-01
9.4e-01
7.5e-01
2.8e+00
9.7e-01
8.6e-01
5.5e-01
cases:21.64%
controls:10.38%
cases:12.56%
controls:5.31%
cases:2.91%
controls:1.40%
cases:0.90%
controls:0.06%
cases:3.03%
controls:1.17%
cases:11.66%
controls:5.31%
cases:15.10%
controls:9.30%
193
926
699
7994
112
474
780
8446
26
125
866
8795
8
5
884
8915
27
104
865
8787
100
449
758
8011
69
434
388
4233
fexofenadine; oral
R06AX26 [21603525]
1.3e+00
1.9e+00
1.3e+00
—
2.1e+00
1.0e+00
1.3e+00
cases:4.71%
controls:1.35%
cases:5.16%
controls:0.82%
cases:0.78%
controls:0.21%
—
—
cases:1.01%
controls:0.12%
cases:2.45%
controls:0.90%
cases:3.94%
controls:1.07%
42
120
850
8800
46
73
846
8847
7
19
885
8901
—
9
11
883
8880
21
76
837
8384
18
50
439
4617
Counselling and guidance which enhance independent living
R2130 [2001310196]
1.2e+00
1.6e+00
—
1.0e+50
3.0e+00
1.9e+00
9.2e-01
cases:4.04%
controls:1.29%
cases:2.47%
controls:0.53%
—
—
cases:0.78%
controls:0.00%
cases:2.24%
controls:0.11%
cases:2.10%
controls:0.33%
cases:3.28%
controls:1.33%
36
115
856
8805
22
47
870
8873
—
7
0
885
8920
20
10
872
8881
18
28
840
8432
15
62
442
4605
Cladosporium herbarum IgE Ab [Units/volume] in Serum
6075-6 [3005136]
2.4e+00
3.7e+00
—
—
—
—
1.4e+00
cases:7.62%
controls:0.72%
cases:7.74%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.28%
controls:0.84%
68
64
824
8856
69
18
823
8902
—
—
—
—
15
39
442
4628
Dermatitis, unspecified
L30.9 [45572271]
1.0e+00
1.1e+00
1.8e+00
—
1.8e+00
1.1e+00
7.2e-01
cases:11.21%
controls:4.24%
cases:4.93%
controls:1.66%
cases:1.23%
controls:0.21%
—
—
cases:1.23%
controls:0.21%
cases:5.13%
controls:1.71%
cases:12.25%
controls:6.36%
100
378
792
8542
44
148
848
8772
11
19
881
8901
—
11
19
881
8872
44
145
814
8315
56
297
401
4370
calcium (different salts in combination); oral
A12AA20 [21600872]
9.8e-01
1.0e+00
6.1e-01
2.3e+00
9.7e-01
1.1e+00
1.2e+00
cases:23.32%
controls:10.21%
cases:19.06%
controls:7.70%
cases:3.92%
controls:2.16%
cases:1.01%
controls:0.10%
cases:5.04%
controls:1.98%
cases:19.23%
controls:7.68%
cases:28.01%
controls:10.91%
208
911
684
8009
170
687
722
8233
35
193
857
8727
9
9
883
8911
45
176
847
8715
165
650
693
7810
128
509
329
4158
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
2.2e+00
3.3e+00
—
—
—
—
2.0e+00
cases:5.61%
controls:0.68%
cases:1.79%
controls:0.07%
—
—
—
—
—
—
—
—
cases:1.97%
controls:0.28%
50
61
842
8859
16
6
876
8914
—
—
—
—
9
13
448
4654
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
1.8e+00
2.4e+00
—
—
—
1.9e+00
1.4e+00
cases:7.17%
controls:1.26%
cases:3.03%
controls:0.29%
—
—
—
—
—
—
cases:1.52%
controls:0.24%
cases:3.28%
controls:0.86%
64
112
828
8808
27
26
865
8894
—
—
—
13
20
845
8440
15
40
442
4627
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.1e+00
2.0e+00
2.2e+00
—
—
1.3e+00
9.2e-01
cases:17.04%
controls:6.67%
cases:11.32%
controls:1.70%
cases:1.46%
controls:0.17%
—
—
—
—
cases:4.90%
controls:1.44%
cases:12.91%
controls:5.57%
152
595
740
8325
101
152
791
8768
13
15
879
8905
—
—
42
122
816
8338
59
260
398
4407
Mycobacterium sp identified in Sputum by Organism specific culture
539-7 [3027544]
2.3e+00
2.7e+00
—
—
—
2.1e+00
2.4e+00
cases:2.80%
controls:0.28%
cases:1.68%
controls:0.11%
—
—
—
—
—
—
cases:0.58%
controls:0.07%
cases:3.06%
controls:0.30%
25
25
867
8895
15
10
877
8910
—
—
—
5
6
853
8454
14
14
443
4653
Dog dander IgE Ab [Units/volume] in Serum
6098-8 [3014133]
2.4e+00
3.8e+00
—
—
—
9.9e-01
1.2e+00
cases:9.19%
controls:0.94%
cases:8.74%
controls:0.22%
—
—
—
—
—
—
cases:0.70%
controls:0.26%
cases:3.28%
controls:0.96%
82
84
810
8836
78
20
814
8900
—
—
—
6
22
852
8438
15
45
442
4622
combinations of corticosteroids
D07XB30 [21602188]
1.1e+00
1.3e+00
1.7e+00
—
1.3e+00
1.1e+00
7.4e-01
cases:32.74%
controls:13.55%
cases:16.03%
controls:4.80%
cases:3.03%
controls:0.56%
—
—
cases:2.02%
controls:0.58%
cases:13.64%
controls:4.80%
cases:24.73%
controls:13.61%
292
1209
600
7711
143
428
749
8492
27
50
865
8870
—
18
52
874
8839
117
406
741
8054
113
635
344
4032
combinations of corticosteroids
D07AB30 [21602118]
1.1e+00
1.3e+00
1.7e+00
—
1.3e+00
1.1e+00
7.4e-01
cases:32.74%
controls:13.55%
cases:16.03%
controls:4.80%
cases:3.03%
controls:0.56%
—
—
cases:2.02%
controls:0.58%
cases:13.64%
controls:4.80%
cases:24.73%
controls:13.61%
292
1209
600
7711
143
428
749
8492
27
50
865
8870
—
18
52
874
8839
117
406
741
8054
113
635
344
4032
glycerol; rectal
A06AG04 [21600587]
2.3e+00
2.4e+00
—
—
—
2.6e+00
—
cases:4.82%
controls:0.53%
cases:1.01%
controls:0.09%
—
—
—
—
—
—
cases:0.93%
controls:0.07%
—
—
43
47
849
8873
9
8
883
8912
—
—
—
8
6
850
8454
—
glycerol
A06AX01 [21600597]
2.3e+00
2.4e+00
—
—
—
2.6e+00
—
cases:4.82%
controls:0.53%
cases:1.01%
controls:0.09%
—
—
—
—
—
—
cases:0.93%
controls:0.07%
—
—
43
47
849
8873
9
8
883
8912
—
—
—
8
6
850
8454
—
Prick test
37968009 [4242723]
2.4e+00
2.8e+00
—
—
—
1.7e+00
2.0e+00
cases:11.66%
controls:1.18%
cases:2.02%
controls:0.12%
—
—
—
—
—
—
cases:0.70%
controls:0.13%
cases:1.75%
controls:0.24%
104
105
788
8815
18
11
874
8909
—
—
—
6
11
852
8449
8
11
449
4656
Measurement of expired nitric oxide
444642008 [40480257]
3.4e+00
—
—
—
—
3.7e+00
—
cases:13.68%
controls:0.50%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.06%
—
—
122
45
770
8875
—
—
—
—
21
5
837
8455
—
doxycycline; oral, parenteral
J01AA02 [21602800]
1.5e+00
1.8e+00
1.6e+00
—
1.0e+00
1.1e+00
1.1e+00
cases:45.18%
controls:15.16%
cases:17.94%
controls:3.44%
cases:2.24%
controls:0.45%
—
—
cases:1.46%
controls:0.52%
cases:9.91%
controls:3.56%
cases:28.67%
controls:11.78%
403
1352
489
7568
160
307
732
8613
20
40
872
8880
—
13
46
879
8845
85
301
773
8159
131
550
326
4117
moxifloxacin; oral, parenteral
J01MA14 [21603021]
1.6e+00
1.9e+00
—
—
—
1.9e+00
1.7e+00
cases:4.71%
controls:1.01%
cases:1.35%
controls:0.20%
—
—
—
—
—
—
cases:1.05%
controls:0.15%
cases:3.06%
controls:0.58%
42
90
850
8830
12
18
880
8902
—
—
—
9
13
849
8447
14
27
443
4640
Functional endoscopic opening of maxillary antrum
DMB20 [2001301780]
3.2e+00
3.9e+00
—
—
—
—
1.5e+00
cases:10.54%
controls:0.47%
cases:2.58%
controls:0.06%
—
—
—
—
—
—
—
—
cases:1.53%
controls:0.34%
94
42
798
8878
23
5
869
8915
—
—
—
—
7
16
450
4651
Skin Pathology biopsy report
65754-4 [40768443]
1.5e+00
2.2e+00
—
—
—
2.0e+00
1.3e+00
cases:7.06%
controls:1.67%
cases:3.59%
controls:0.43%
—
—
—
—
—
—
cases:2.68%
controls:0.35%
cases:4.60%
controls:1.29%
63
149
829
8771
32
38
860
8882
—
—
—
23
30
835
8430
21
60
436
4607
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
1.8e+00
1.5e+00
—
9.8e-01
1.1e+00
1.3e+00
cases:32.29%
controls:11.67%
cases:17.26%
controls:3.45%
cases:1.68%
controls:0.37%
—
—
cases:1.01%
controls:0.38%
cases:9.67%
controls:3.42%
cases:29.32%
controls:10.39%
288
1041
604
7879
154
308
738
8612
15
33
877
8887
—
9
34
883
8857
83
289
775
8171
134
485
323
4182
Chronic rhinitis
J31.0 [45572165]
1.6e+00
1.3e+00
2.5e+00
—
—
1.5e+00
5.9e-01
cases:6.61%
controls:1.37%
cases:2.24%
controls:0.64%
cases:0.78%
controls:0.07%
—
—
—
—
cases:2.21%
controls:0.50%
cases:3.06%
controls:1.71%
59
122
833
8798
20
57
872
8863
7
6
885
8914
—
—
19
42
839
8418
14
80
443
4587
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
1.3e+00
2.0e+00
—
—
—
1.8e+00
1.8e+00
cases:4.82%
controls:1.35%
cases:2.35%
controls:0.34%
—
—
—
—
—
—
cases:1.86%
controls:0.31%
cases:3.50%
controls:0.62%
43
120
849
8800
21
30
871
8890
—
—
—
16
26
842
8434
16
29
441
4638
Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum
53017-0 [3041067]
1.0e+00
2.5e+00
—
—
—
2.3e+00
2.0e+00
cases:1.23%
controls:0.45%
cases:1.68%
controls:0.13%
—
—
—
—
—
—
cases:0.93%
controls:0.09%
cases:1.97%
controls:0.28%
11
40
881
8880
15
12
877
8908
—
—
—
8
8
850
8452
9
13
448
4654
Asthma
R96 [2002000961]
2.1e+00
2.1e+00
1.8e+00
—
—
1.0e+00
1.5e+00
cases:14.46%
controls:2.04%
cases:5.16%
controls:0.68%
cases:0.56%
controls:0.09%
—
—
—
—
cases:2.21%
controls:0.83%
cases:10.07%
controls:2.38%
129
182
763
8738
46
61
846
8859
5
8
887
8912
—
—
19
70
839
8390
46
111
411
4556
Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
35333-4 [3036086]
1.0e+00
2.3e+00
—
—
—
1.9e+00
1.5e+00
cases:2.80%
controls:1.02%
cases:3.14%
controls:0.34%
—
—
—
—
—
—
cases:1.86%
controls:0.28%
cases:4.81%
controls:1.14%
25
91
867
8829
28
30
864
8890
—
—
—
16
24
842
8436
22
53
435
4614
mometasone; nasal
R01AD09 [21605051]
1.1e+00
1.1e+00
1.6e+00
—
1.5e+00
9.3e-01
5.1e-01
cases:24.44%
controls:9.93%
cases:10.65%
controls:3.87%
cases:2.80%
controls:0.58%
—
—
cases:2.24%
controls:0.53%
cases:8.74%
controls:3.65%
cases:13.35%
controls:8.46%
218
886
674
8034
95
345
797
8575
25
52
867
8868
—
20
47
872
8844
75
309
783
8151
61
395
396
4272
budesonide; oral, sublingual
A07EA06 [21600658]
1.4e+00
1.6e+00
—
—
—
1.6e+00
1.9e+00
cases:4.04%
controls:1.00%
cases:1.79%
controls:0.36%
—
—
—
—
—
—
cases:1.98%
controls:0.39%
cases:5.25%
controls:0.84%
36
89
856
8831
16
32
876
8888
—
—
—
17
33
841
8427
24
39
433
4628
Extractable nuclear Ab panel - Serum
43119-7 [3029075]
—
2.2e+00
—
—
—
2.6e+00
1.8e+00
—
—
cases:0.78%
controls:0.09%
—
—
—
—
—
—
cases:0.82%
controls:0.06%
cases:2.19%
controls:0.39%
—
7
8
885
8912
—
—
—
7
5
851
8455
10
18
447
4649
Thorax CT examination
GD1AD [2001303618]
1.1e+00
2.0e+00
—
—
—
1.8e+00
1.6e+00
cases:2.35%
controls:0.78%
cases:2.24%
controls:0.31%
—
—
—
—
—
—
cases:1.86%
controls:0.31%
cases:4.60%
controls:0.96%
21
70
871
8850
20
28
872
8892
—
—
—
16
26
842
8434
21
45
436
4622
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
9.9e-01
1.4e+00
2.1e+00
—
1.3e+00
1.0e+00
1.0e+00
cases:13.23%
controls:5.35%
cases:6.84%
controls:1.84%
cases:1.12%
controls:0.13%
—
—
cases:0.78%
controls:0.21%
cases:5.01%
controls:1.88%
cases:11.82%
controls:4.65%
118
477
774
8443
61
164
831
8756
10
12
882
8908
—
7
19
885
8872
43
159
815
8301
54
217
403
4450
SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
26975-3 [3025245]
8.8e-01
2.3e+00
—
—
—
2.0e+00
1.4e+00
cases:2.13%
controls:0.90%
cases:2.91%
controls:0.30%
—
—
—
—
—
—
cases:1.98%
controls:0.28%
cases:4.38%
controls:1.16%
19
80
873
8840
26
27
866
8893
—
—
—
17
24
841
8436
20
54
437
4613
ketotifen
S01GX08 [21605092]
1.3e+00
1.5e+00
1.8e+00
—
—
2.1e+00
1.6e+00
cases:2.80%
controls:0.75%
cases:1.68%
controls:0.39%
cases:0.56%
controls:0.09%
—
—
—
—
cases:2.56%
controls:0.33%
cases:4.81%
controls:1.05%
25
67
867
8853
15
35
877
8885
5
8
887
8912
—
—
22
28
836
8432
22
49
435
4618
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
6.2e-01
1.3e+00
7.2e-01
1.3e+00
5.8e-01
9.6e-01
8.9e-01
cases:71.19%
controls:57.13%
cases:71.30%
controls:39.85%
cases:15.47%
controls:8.15%
cases:1.23%
controls:0.34%
cases:13.90%
controls:8.28%
cases:63.52%
controls:40.00%
cases:81.18%
controls:63.90%
635
5096
257
3824
636
3555
256
5365
138
727
754
8193
11
30
881
8890
124
736
768
8155
545
3384
313
5076
371
2982
86
1685
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
1.1e+00
1.4e+00
2.9e+00
—
—
9.6e-01
4.8e-01
cases:6.50%
controls:2.25%
cases:2.80%
controls:0.72%
cases:1.01%
controls:0.06%
—
—
—
—
cases:2.10%
controls:0.82%
cases:4.16%
controls:2.61%
58
201
834
8719
25
64
867
8856
9
5
883
8915
—
—
18
69
840
8391
19
122
438
4545
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.5e+00
1.8e+00
1.1e+00
—
—
1.4e+00
1.6e+00
cases:6.84%
controls:1.55%
cases:2.80%
controls:0.47%
cases:0.56%
controls:0.18%
—
—
—
—
cases:1.75%
controls:0.45%
cases:4.81%
controls:1.01%
61
138
831
8782
25
42
867
8878
5
16
887
8904
—
—
15
38
843
8422
22
47
435
4620
zinc bandage without supplements
D09AB01 [21602278]
2.8e+00
3.5e+00
—
—
—
—
—
cases:2.80%
controls:0.18%
cases:1.79%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
25
16
867
8904
16
5
876
8915
—
—
—
—
—
zinc preparations; ointment
C05AX04 [21601632]
2.8e+00
3.5e+00
—
—
—
—
—
cases:2.80%
controls:0.18%
cases:1.79%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
25
16
867
8904
16
5
876
8915
—
—
—
—
—
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
7.6e-01
2.5e+00
—
—
—
1.4e+00
1.5e+00
cases:3.36%
controls:1.60%
cases:4.93%
controls:0.40%
—
—
—
—
—
—
cases:1.17%
controls:0.28%
cases:4.16%
controls:0.96%
30
143
862
8777
44
36
848
8884
—
—
—
10
24
848
8436
19
45
438
4622
nystatin; oral
A07AA02 [21600604]
1.3e+00
1.5e+00
—
—
—
1.7e+00
1.7e+00
cases:3.92%
controls:1.09%
cases:1.35%
controls:0.31%
—
—
—
—
—
—
cases:1.17%
controls:0.21%
cases:3.28%
controls:0.60%
35
97
857
8823
12
28
880
8892
—
—
—
10
18
848
8442
15
28
442
4639
antibiotics in combination with other drugs
S01AA20 [21603571]
7.8e-01
9.7e-01
1.7e+00
—
1.7e+00
1.1e+00
4.4e-01
cases:18.27%
controls:9.27%
cases:6.28%
controls:2.48%
cases:1.46%
controls:0.28%
—
—
cases:1.12%
controls:0.21%
cases:7.46%
controls:2.58%
cases:12.04%
controls:8.10%
163
827
729
8093
56
221
836
8699
13
25
879
8895
—
10
19
882
8872
64
218
794
8242
55
378
402
4289
Nuclear Ab [Presence] in Serum
8061-4 [3004616]
1.2e+00
2.5e+00
—
—
—
2.5e+00
1.7e+00
cases:2.02%
controls:0.63%
cases:1.79%
controls:0.15%
—
—
—
—
—
—
cases:0.70%
controls:0.06%
cases:1.31%
controls:0.24%
18
56
874
8864
16
13
876
8907
—
—
—
6
5
852
8455
6
11
451
4656
Prurigo nodularis
L28.1 [45577033]
3.5e+00
—
—
1.0e+50
1.0e+50
—
2.6e+00
cases:3.03%
controls:0.09%
—
—
—
—
cases:0.67%
controls:0.00%
cases:2.02%
controls:0.00%
—
—
cases:1.75%
controls:0.13%
27
8
865
8912
—
—
6
0
886
8920
18
0
874
8891
—
8
6
449
4661
Sleep apnoea
G47.3 [45562094]
7.8e-01
8.7e-01
1.3e+00
—
1.4e+00
8.8e-01
8.3e-01
cases:17.49%
controls:8.82%
cases:12.67%
controls:5.71%
cases:4.26%
controls:1.14%
—
—
cases:4.71%
controls:1.21%
cases:13.75%
controls:6.19%
cases:22.54%
controls:11.23%
156
787
736
8133
113
509
779
8411
38
102
854
8818
—
42
108
850
8783
118
524
740
7936
103
524
354
4143
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
9.7e-01
1.2e+00
5.5e-01
1.2e+00
3.5e-01
6.8e-01
1.1e+00
cases:89.46%
controls:76.26%
cases:77.58%
controls:51.83%
cases:16.37%
controls:10.13%
cases:1.35%
controls:0.39%
cases:13.45%
controls:9.83%
cases:68.07%
controls:51.99%
cases:93.22%
controls:81.77%
798
6802
94
2118
692
4623
200
4297
146
904
746
8016
12
35
880
8885
120
874
772
8017
584
4398
274
4062
426
3816
31
851
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
1.2e+00
1.4e+00
1.5e+00
—
1.1e+00
1.0e+00
1.0e+00
cases:27.02%
controls:10.44%
cases:9.98%
controls:2.59%
cases:1.23%
controls:0.29%
—
—
cases:0.56%
controls:0.18%
cases:6.53%
controls:2.49%
cases:19.26%
controls:7.97%
241
931
651
7989
89
231
803
8689
11
26
881
8894
—
5
16
887
8875
56
211
802
8249
88
372
369
4295
Remote contact by phone
ZYC01 [2001311579]
6.3e-01
1.3e+00
2.3e+00
—
—
1.4e+00
9.9e-01
cases:2.58%
controls:1.39%
cases:2.58%
controls:0.70%
cases:0.90%
controls:0.09%
—
—
—
—
cases:2.21%
controls:0.56%
cases:3.94%
controls:1.50%
23
124
869
8796
23
62
869
8858
8
8
884
8912
—
—
19
47
839
8413
18
70
439
4597
olopatadine
R01AC08 [21605040]
1.9e+00
1.4e+00
1.7e+00
—
—
1.5e+00
1.3e+00
cases:1.12%
controls:0.17%
cases:2.13%
controls:0.56%
cases:0.56%
controls:0.10%
—
—
—
—
cases:4.66%
controls:1.11%
cases:13.35%
controls:4.05%
10
15
882
8905
19
50
873
8870
5
9
887
8911
—
—
40
94
818
8366
61
189
396
4478
mometasone, combinations
R01AD59 [947911]
1.9e+00
1.4e+00
1.7e+00
—
—
1.5e+00
1.3e+00
cases:1.12%
controls:0.17%
cases:2.13%
controls:0.56%
cases:0.56%
controls:0.10%
—
—
—
—
cases:4.66%
controls:1.11%
cases:13.35%
controls:4.05%
10
15
882
8905
19
50
873
8870
5
9
887
8911
—
—
40
94
818
8366
61
189
396
4478
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.1e+00
1.5e+00
1.2e+00
—
3.2e-01
1.1e+00
1.1e+00
cases:68.27%
controls:41.11%
cases:48.88%
controls:17.19%
cases:7.40%
controls:2.31%
—
—
cases:3.59%
controls:2.62%
cases:35.55%
controls:16.04%
cases:62.80%
controls:36.90%
609
3667
283
5253
436
1533
456
7387
66
206
826
8714
—
32
233
860
8658
305
1357
553
7103
287
1722
170
2945
formoterol and budesonide
R03AK07 [21603281]
1.2e+00
1.2e+00
1.3e+00
—
1.4e+00
8.4e-01
1.3e-01
cases:13.23%
controls:4.36%
cases:6.61%
controls:2.03%
cases:1.68%
controls:0.47%
—
—
cases:1.79%
controls:0.44%
cases:5.36%
controls:2.38%
cases:6.13%
controls:5.42%
118
389
774
8531
59
181
833
8739
15
42
877
8878
—
16
39
876
8852
46
201
812
8259
28
253
429
4414
antibiotics in combination with corticosteroids
D01AA20 [21601918]
2.0e+00
2.3e+00
—
—
—
1.7e+00
1.1e+00
cases:7.51%
controls:1.07%
cases:2.35%
controls:0.25%
—
—
—
—
—
—
cases:1.52%
controls:0.28%
cases:2.19%
controls:0.75%
67
95
825
8825
21
22
871
8898
—
—
—
13
24
845
8436
10
35
447
4632
Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum
29374-6 [3006999]
8.4e-01
2.1e+00
—
—
—
1.7e+00
1.3e+00
cases:2.91%
controls:1.28%
cases:3.03%
controls:0.38%
—
—
—
—
—
—
cases:1.86%
controls:0.34%
cases:4.38%
controls:1.22%
26
114
866
8806
27
34
865
8886
—
—
—
16
29
842
8431
20
57
437
4610
Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma
10634-4 [3023659]
3.1e+00
—
—
—
—
—
2.8e+00
cases:2.02%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.11%
18
8
874
8912
—
—
—
—
—
8
5
449
4662
Smith extractable nuclear Ab [Units/volume] in Serum
11090-8 [3016921]
8.4e-01
2.1e+00
—
—
—
1.7e+00
1.3e+00
cases:2.91%
controls:1.28%
cases:3.03%
controls:0.39%
—
—
—
—
—
—
cases:1.86%
controls:0.34%
cases:4.38%
controls:1.24%
26
114
866
8806
27
35
865
8885
—
—
—
16
29
842
8431
20
58
437
4609
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.5e+00
1.8e+00
—
—
—
1.2e+00
1.4e+00
cases:10.43%
controls:2.50%
cases:4.71%
controls:0.78%
—
—
—
—
—
—
cases:2.10%
controls:0.64%
cases:7.00%
controls:1.91%
93
223
799
8697
42
70
850
8850
—
—
—
18
54
840
8406
32
89
425
4578
triamcinolone; nasal
R01AD11 [21605052]
1.5e+00
2.3e+00
—
—
—
2.1e+00
—
cases:1.79%
controls:0.41%
cases:1.01%
controls:0.10%
—
—
—
—
—
—
cases:1.05%
controls:0.13%
—
—
16
37
876
8883
9
9
883
8911
—
—
—
9
11
849
8449
—
Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum
17791-5 [3027450]
8.9e-01
2.0e+00
—
—
—
1.8e+00
1.2e+00
cases:3.25%
controls:1.37%
cases:3.03%
controls:0.40%
—
—
—
—
—
—
cases:1.98%
controls:0.34%
cases:4.38%
controls:1.41%
29
122
863
8798
27
36
865
8884
—
—
—
17
29
841
8431
20
66
437
4601
Other intravascular therapy with radiological guidance
XX6XT [2001311146]
2.6e+00
3.2e+00
1.0e+50
—
—
—
—
cases:0.90%
controls:0.07%
cases:1.68%
controls:0.07%
cases:1.12%
controls:0.00%
—
—
—
—
—
—
—
—
8
6
884
8914
15
6
877
8914
10
0
882
8920
—
—
—
—
Audiology
64 [38004489]
9.9e-01
1.3e+00
1.4e+00
—
1.7e+00
1.0e+00
8.3e-01
cases:8.30%
controls:3.25%
cases:4.48%
controls:1.28%
cases:0.90%
controls:0.22%
—
—
cases:0.90%
controls:0.17%
cases:3.50%
controls:1.30%
cases:7.00%
controls:3.19%
74
290
818
8630
40
114
852
8806
8
20
884
8900
—
8
15
884
8876
30
110
828
8350
32
149
425
4518
Milk IgE Ab [Units/volume] in Serum
6174-7 [3020874]
2.3e+00
3.4e+00
—
—
—
-1.0e+50
—
cases:3.03%
controls:0.30%
cases:1.68%
controls:0.06%
—
—
—
—
—
—
cases:0.00%
controls:0.08%
—
—
27
27
865
8893
15
5
877
8915
—
—
—
0
7
858
8453
—
Infective dermatitis
L30.3 [45577034]
2.0e+00
2.1e+00
—
—
—
1.7e+00
1.4e+00
cases:2.13%
controls:0.29%
cases:1.23%
controls:0.16%
—
—
—
—
—
—
cases:1.05%
controls:0.20%
cases:1.75%
controls:0.45%
19
26
873
8894
11
14
881
8906
—
—
—
9
17
849
8443
8
21
449
4646
Dust mix specific IgE antibody measurement
849121000000107 [44813793]
2.4e+00
3.3e+00
—
—
—
—
—
cases:2.69%
controls:0.26%
cases:1.79%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
24
23
868
8897
16
6
876
8914
—
—
—
—
—
Instruction on medicine inhalation technique
ZX109 [2001311490]
3.1e+00
2.6e+00
—
—
—
—
—
cases:2.35%
controls:0.11%
cases:0.90%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
21
10
871
8910
8
6
884
8914
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.3e+00
1.3e+00
8.7e-01
1.1e+00
3.8e-01
8.7e-01
1.2e+00
cases:88.00%
controls:66.26%
cases:67.83%
controls:35.61%
cases:14.13%
controls:6.43%
cases:0.90%
controls:0.31%
cases:9.42%
controls:6.65%
cases:55.48%
controls:34.26%
cases:85.56%
controls:63.47%
785
5910
107
3010
605
3176
287
5744
126
574
766
8346
8
28
884
8892
84
591
808
8300
476
2898
382
5562
391
2962
66
1705
Dyspnoea
R06.0 [45558449]
1.1e+00
1.3e+00
1.9e+00
—
6.5e-01
6.9e-01
6.2e-01
cases:14.91%
controls:5.48%
cases:6.28%
controls:1.82%
cases:1.23%
controls:0.19%
—
—
cases:0.56%
controls:0.29%
cases:3.96%
controls:2.02%
cases:10.07%
controls:5.66%
133
489
759
8431
56
162
836
8758
11
17
881
8903
—
5
26
887
8865
34
171
824
8289
46
264
411
4403
roxithromycin; oral
J01FA06 [21602974]
1.9e+00
1.9e+00
—
—
—
1.7e+00
1.1e+00
cases:7.17%
controls:1.14%
cases:1.57%
controls:0.25%
—
—
—
—
—
—
cases:0.93%
controls:0.17%
cases:1.53%
controls:0.54%
64
102
828
8818
14
22
878
8898
—
—
—
8
14
850
8446
7
25
450
4642
Patch test
41778007 [4218642]
2.5e+00
3.0e+00
—
—
—
2.0e+00
—
cases:6.28%
controls:0.57%
cases:1.91%
controls:0.10%
—
—
—
—
—
—
cases:0.58%
controls:0.08%
—
—
56
51
836
8869
17
9
875
8911
—
—
—
5
7
853
8453
—
U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum
59026-5 [40762119]
9.9e-01
1.9e+00
—
—
—
2.5e+00
1.2e+00
cases:1.79%
controls:0.67%
cases:1.23%
controls:0.19%
—
—
—
—
—
—
cases:1.28%
controls:0.11%
cases:1.97%
controls:0.58%
16
60
876
8860
11
17
881
8903
—
—
—
11
9
847
8451
9
27
448
4640
Casein IgE Ab [Units/volume] in Serum
6062-4 [3011897]
2.6e+00
—
—
—
—
—
2.7e+00
cases:1.35%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:1.97%
controls:0.13%
12
9
880
8911
—
—
—
—
—
9
6
448
4661
Egg white IgE Ab [Units/volume] in Serum
6106-9 [3014599]
2.4e+00
2.9e+00
—
—
—
—
—
cases:3.48%
controls:0.31%
cases:1.57%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
31
28
861
8892
14
8
878
8912
—
—
—
—
—
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
8.1e-01
1.8e+00
—
—
—
1.5e+00
1.3e+00
cases:4.71%
controls:2.14%
cases:3.48%
controls:0.62%
—
—
—
—
—
—
cases:2.45%
controls:0.58%
cases:5.25%
controls:1.52%
42
191
850
8729
31
55
861
8865
—
—
—
21
49
837
8411
24
71
433
4596
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.5e+00
1.6e+00
1.4e+00
—
1.2e+00
9.7e-01
1.3e+00
cases:13.79%
controls:3.60%
cases:6.61%
controls:1.41%
cases:0.56%
controls:0.15%
—
—
cases:0.56%
controls:0.17%
cases:3.15%
controls:1.22%
cases:10.07%
controls:3.00%
123
321
769
8599
59
126
833
8794
5
13
887
8907
—
5
15
887
8876
27
103
831
8357
46
140
411
4527
hydrocortisone and antiinfectives
S01CA03 [21603654]
1.8e+00
2.0e+00
—
—
—
1.5e+00
8.0e-01
cases:7.06%
controls:1.29%
cases:2.47%
controls:0.34%
—
—
—
—
—
—
cases:1.75%
controls:0.39%
cases:2.41%
controls:1.09%
63
115
829
8805
22
30
870
8890
—
—
—
15
33
843
8427
11
51
446
4616
beclometasone; nasal
R01AD01 [21605043]
1.2e+00
1.4e+00
—
—
—
1.4e+00
1.3e+00
cases:3.48%
controls:1.08%
cases:1.35%
controls:0.34%
—
—
—
—
—
—
cases:1.63%
controls:0.43%
cases:2.41%
controls:0.66%
31
96
861
8824
12
30
880
8890
—
—
—
14
36
844
8424
11
31
446
4636
Acute maxillary sinusitis
J01.0 [45601112]
1.2e+00
9.0e-01
1.6e+00
—
5.4e-01
6.5e-01
7.6e-01
cases:17.71%
controls:6.11%
cases:5.72%
controls:2.41%
cases:1.35%
controls:0.27%
—
—
cases:0.67%
controls:0.39%
cases:5.48%
controls:2.93%
cases:15.75%
controls:8.06%
158
545
734
8375
51
215
841
8705
12
24
880
8896
—
6
35
886
8856
47
248
811
8212
72
376
385
4291
Aspergillus sp Ab [Presence] in Serum
7808-9 [3008536]
2.6e+00
2.5e+00
—
—
—
—
—
cases:1.01%
controls:0.08%
cases:0.67%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
9
7
883
8913
6
5
886
8915
—
—
—
—
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.9e-01
4.4e-01
2.1e-01
2.1e+00
5.7e-01
6.1e-01
7.1e-01
cases:66.37%
controls:52.17%
cases:35.76%
controls:26.31%
cases:4.93%
controls:4.05%
cases:1.01%
controls:0.12%
cases:7.29%
controls:4.25%
cases:39.74%
controls:26.29%
cases:67.61%
controls:50.57%
592
4654
300
4266
319
2347
573
6573
44
361
848
8559
9
11
883
8909
65
378
827
8513
341
2224
517
6236
309
2360
148
2307
ambroxol; oral
R05CB06 [21603385]
1.2e+00
1.4e+00
1.8e+00
—
2.0e+00
1.3e+00
1.0e+00
cases:18.27%
controls:6.10%
cases:5.27%
controls:1.31%
cases:0.67%
controls:0.11%
—
—
cases:0.56%
controls:0.08%
cases:4.20%
controls:1.15%
cases:9.63%
controls:3.64%
163
544
729
8376
47
117
845
8803
6
10
886
8910
—
5
7
887
8884
36
97
822
8363
44
170
413
4497
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
6.4e-01
8.7e-01
5.4e-01
1.4e+00
3.9e-01
6.3e-01
9.5e-01
cases:72.42%
controls:58.12%
cases:61.32%
controls:39.89%
cases:12.89%
controls:7.95%
cases:1.35%
controls:0.34%
cases:10.43%
controls:7.32%
cases:56.06%
controls:40.43%
cases:86.00%
controls:70.34%
646
5184
246
3736
547
3558
345
5362
115
709
777
8211
12
30
880
8890
93
651
799
8240
481
3420
377
5040
393
3283
64
1384
Allergy, unspecified
T78.4 [45580373]
1.6e+00
2.0e+00
—
—
—
1.5e+00
1.5e+00
cases:3.25%
controls:0.71%
cases:1.23%
controls:0.17%
—
—
—
—
—
—
cases:0.93%
controls:0.21%
cases:2.19%
controls:0.51%
29
63
863
8857
11
15
881
8905
—
—
—
8
18
850
8442
10
24
447
4643
Observation for other suspected diseases and conditions
Z03.80 [2000503756]
1.1e+00
1.7e+00
—
—
—
—
2.2e+00
cases:1.46%
controls:0.49%
cases:0.90%
controls:0.17%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.19%
13
44
879
8876
8
15
884
8905
—
—
—
—
8
9
449
4658
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
1.1e+00
1.6e+00
—
—
2.3e+00
1.2e+00
1.2e+00
cases:3.14%
controls:1.07%
cases:1.79%
controls:0.38%
—
—
—
—
cases:0.67%
controls:0.07%
cases:1.17%
controls:0.37%
cases:2.41%
controls:0.77%
28
95
864
8825
16
34
876
8886
—
—
6
6
886
8885
10
31
848
8429
11
36
446
4631
Allergic contact dermatitis due to cosmetics
L23.2 [45572265]
2.5e+00
—
—
—
1.0e+50
2.4e+00
—
cases:1.79%
controls:0.15%
—
—
—
—
—
—
cases:0.67%
controls:0.00%
cases:0.93%
controls:0.08%
—
—
16
13
876
8907
—
—
—
6
0
886
8891
8
7
850
8453
—
Spirometry study
18759-1 [3000492]
1.5e+00
1.7e+00
—
—
—
1.1e+00
6.9e-01
cases:19.28%
controls:5.04%
cases:5.72%
controls:1.13%
—
—
—
—
—
—
cases:2.80%
controls:0.98%
cases:6.78%
controls:3.54%
172
450
720
8470
51
101
841
8819
—
—
—
24
83
834
8377
31
165
426
4502
Other specified counselling
Z71.8 [45581061]
3.7e-01
7.6e-01
1.2e+00
—
1.5e+00
5.3e-01
6.0e-01
cases:14.57%
controls:10.52%
cases:10.09%
controls:4.97%
cases:2.58%
controls:0.82%
—
—
cases:2.69%
controls:0.62%
cases:8.86%
controls:5.43%
cases:26.04%
controls:16.20%
130
938
762
7982
90
443
802
8477
23
73
869
8847
—
24
55
868
8836
76
459
782
8001
119
756
338
3911
Dermatitis/atopic eczema
S87 [2002001051]
2.2e+00
2.7e+00
—
—
—
1.8e+00
1.4e+00
cases:3.36%
controls:0.37%
cases:1.12%
controls:0.08%
—
—
—
—
—
—
cases:0.58%
controls:0.09%
cases:1.31%
controls:0.34%
30
33
862
8887
10
7
882
8913
—
—
—
5
8
853
8452
6
16
451
4651
ranitidine; oral, parenteral
A02BA02 [21600083]
1.8e+00
3.1e+00
—
—
—
—
—
cases:3.25%
controls:0.54%
cases:1.68%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
29
48
863
8872
15
7
877
8913
—
—
—
—
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
1.8e+00
3.1e+00
—
—
—
—
—
cases:3.25%
controls:0.54%
cases:1.68%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
29
48
863
8872
15
7
877
8913
—
—
—
—
—
Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma
1825-9 [3026285]
1.4e+00
2.0e+00
—
—
—
—
1.4e+00
cases:2.58%
controls:0.63%
cases:1.46%
controls:0.19%
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.54%
23
56
869
8864
13
17
879
8903
—
—
—
—
10
25
447
4642
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
2.2e+00
2.7e+00
—
—
—
—
—
cases:12.44%
controls:1.56%
cases:3.92%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
111
139
781
8781
35
25
857
8895
—
—
—
—
—
Open wound of other parts of lower leg
S81.8 [45564809]
1.3e+00
1.8e+00
—
—
—
—
1.7e+00
cases:1.46%
controls:0.39%
cases:0.78%
controls:0.13%
—
—
—
—
—
—
—
—
cases:2.41%
controls:0.43%
13
35
879
8885
7
12
885
8908
—
—
—
—
11
20
446
4647
Flexible bronchoscopy
UGC12 [2001303610]
2.0e+00
2.9e+00
—
—
—
1.2e+00
9.0e-01
cases:4.15%
controls:0.61%
cases:2.13%
controls:0.12%
—
—
—
—
—
—
cases:0.58%
controls:0.18%
cases:1.31%
controls:0.54%
37
54
855
8866
19
11
873
8909
—
—
—
5
15
853
8445
6
25
451
4642
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.3e+00
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:7.17%
controls:2.06%
cases:1.57%
controls:0.53%
—
—
—
—
—
—
cases:1.86%
controls:0.54%
cases:4.81%
controls:1.61%
64
184
828
8736
14
47
878
8873
—
—
—
16
46
842
8414
22
75
435
4592
Angioneurotic oedema
T78.3 [45551447]
2.2e+00
—
1.0e+50
—
—
—
2.5e+00
cases:1.23%
controls:0.13%
—
—
cases:0.67%
controls:0.00%
—
—
—
—
—
—
cases:1.31%
controls:0.11%
11
12
881
8908
—
6
0
886
8920
—
—
—
6
5
451
4662
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
2.3e-01
1.4e+00
2.5e+00
—
—
5.9e-01
8.0e-01
cases:5.38%
controls:4.30%
cases:5.38%
controls:1.35%
cases:1.35%
controls:0.11%
—
—
—
—
cases:1.98%
controls:1.11%
cases:7.66%
controls:3.58%
48
384
844
8536
48
120
844
8800
12
10
880
8910
—
—
17
94
841
8366
35
167
422
4500
Soybean IgE Ab [Units/volume] in Serum
6248-9 [3015076]
2.1e+00
2.7e+00
—
—
—
—
1.1e+00
cases:2.24%
controls:0.29%
cases:1.12%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.09%
controls:0.36%
20
26
872
8894
10
7
882
8913
—
—
—
—
5
17
452
4650
Adjustment or review of hearing aid
DAX00 [2001301528]
1.3e+00
1.8e+00
—
—
—
1.1e+00
1.5e+00
cases:1.91%
controls:0.53%
cases:1.12%
controls:0.18%
—
—
—
—
—
—
cases:0.58%
controls:0.20%
cases:2.63%
controls:0.58%
17
47
875
8873
10
16
882
8904
—
—
—
5
17
853
8443
12
27
445
4640
Fungus identified in Specimen by Culture
580-1 [3000494]
1.3e+00
1.7e+00
—
—
—
7.8e-01
9.3e-01
cases:14.80%
controls:4.69%
cases:7.17%
controls:1.40%
—
—
—
—
—
—
cases:2.80%
controls:1.30%
cases:9.85%
controls:4.11%
132
418
760
8502
64
125
828
8795
—
—
—
24
110
834
8350
45
192
412
4475
prednisolone
S01BA04 [21603621]
1.0e+00
1.2e+00
—
—
—
1.5e+00
1.0e+00
cases:7.96%
controls:3.04%
cases:3.59%
controls:1.15%
—
—
—
—
—
—
cases:3.85%
controls:0.91%
cases:7.22%
controls:2.76%
71
271
821
8649
32
103
860
8817
—
—
—
33
77
825
8383
33
129
424
4538
prednisolone
S03BA02 [21605202]
1.0e+00
1.2e+00
—
—
—
1.5e+00
1.0e+00
cases:7.96%
controls:3.04%
cases:3.59%
controls:1.15%
—
—
—
—
—
—
cases:3.85%
controls:0.91%
cases:7.22%
controls:2.76%
71
271
821
8649
32
103
860
8817
—
—
—
33
77
825
8383
33
129
424
4538
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
1.1e+00
1.9e+00
—
—
—
—
1.6e+00
cases:3.48%
controls:1.19%
cases:1.01%
controls:0.15%
—
—
—
—
—
—
—
—
cases:1.97%
controls:0.41%
31
106
861
8814
9
13
883
8907
—
—
—
—
9
19
448
4648
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood
64084-7 [40766800]
7.0e-01
2.6e+00
—
—
—
—
2.0e+00
cases:1.23%
controls:0.62%
cases:2.02%
controls:0.15%
—
—
—
—
—
—
—
—
cases:1.53%
controls:0.21%
11
55
881
8865
18
13
874
8907
—
—
—
—
7
10
450
4657
Polypectomy of internal nose
DHB20 [2001301689]
4.6e+00
1.0e+50
—
—
—
—
—
cases:7.40%
controls:0.08%
cases:2.02%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
66
7
826
8913
18
0
874
8920
—
—
—
—
—
Pneumonia, unspecified
J18.9 [45601123]
1.3e+00
1.5e+00
—
—
1.4e+00
7.6e-01
1.0e+00
cases:11.10%
controls:3.17%
cases:4.71%
controls:1.10%
—
—
—
—
cases:0.56%
controls:0.13%
cases:2.91%
controls:1.38%
cases:10.50%
controls:4.16%
99
283
793
8637
42
98
850
8822
—
—
5
12
887
8879
25
117
833
8343
48
194
409
4473
Microscopic observation [Identifier] in Buccal smear by Cyto stain
18501-7 [3018559]
1.9e+00
2.6e+00
—
—
—
—
—
cases:1.91%
controls:0.29%
cases:1.23%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
17
26
875
8894
11
8
881
8912
—
—
—
—
—
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
1.0e+00
1.5e+00
—
—
—
—
2.0e+00
cases:1.79%
controls:0.66%
cases:1.12%
controls:0.26%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.24%
16
59
876
8861
10
23
882
8897
—
—
—
—
8
11
449
4656
ciclosporin
S01XA18 [21605142]
—
—
—
—
—
2.2e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:0.82%
controls:0.09%
cases:1.31%
controls:0.13%
—
—
—
—
—
7
8
851
8452
6
6
451
4661
Zinc [Moles/volume] in Serum or Plasma
14955-9 [3020717]
2.0e+00
2.5e+00
—
—
—
1.8e+00
1.0e+00
cases:1.79%
controls:0.25%
cases:1.35%
controls:0.11%
—
—
—
—
—
—
cases:0.58%
controls:0.09%
cases:1.09%
controls:0.39%
16
22
876
8898
12
10
880
8910
—
—
—
5
8
853
8452
5
18
452
4649
Anaphylactic shock, unspecified
T78.2 [45537000]
2.2e+00
2.3e+00
1.0e+50
—
—
—
—
cases:0.78%
controls:0.09%
cases:0.67%
controls:0.07%
cases:0.56%
controls:0.00%
—
—
—
—
—
—
—
—
7
8
885
8912
6
6
886
8914
5
0
887
8920
—
—
—
—
Allergic urticaria
L50.0 [45581945]
2.1e+00
—
—
—
—
—
2.3e+00
cases:1.79%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:1.53%
controls:0.15%
16
19
876
8901
—
—
—
—
—
7
7
450
4660
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
1.1e+00
1.7e+00
—
—
—
8.6e-01
1.6e+00
cases:2.58%
controls:0.85%
cases:1.35%
controls:0.25%
—
—
—
—
—
—
cases:0.58%
controls:0.25%
cases:4.16%
controls:0.84%
23
76
869
8844
12
22
880
8898
—
—
—
5
21
853
8439
19
39
438
4628
dexrabeprazole
A02BC07 [45893509]
1.0e+00
9.9e-01
1.5e+00
—
—
1.2e+00
1.3e+00
cases:4.26%
controls:1.61%
cases:1.91%
controls:0.72%
cases:0.67%
controls:0.16%
—
—
—
—
cases:2.68%
controls:0.82%
cases:4.60%
controls:1.35%
38
144
854
8776
17
64
875
8856
6
14
886
8906
—
—
23
69
835
8391
21
63
436
4604
rabeprazole; oral
A02BC04 [21600099]
1.0e+00
9.9e-01
1.5e+00
—
—
1.2e+00
1.3e+00
cases:4.26%
controls:1.61%
cases:1.91%
controls:0.72%
cases:0.67%
controls:0.16%
—
—
—
—
cases:2.68%
controls:0.82%
cases:4.60%
controls:1.35%
38
144
854
8776
17
64
875
8856
6
14
886
8906
—
—
23
69
835
8391
21
63
436
4604
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
1.1e+00
2.0e+00
—
—
—
7.2e-01
1.3e+00
cases:1.79%
controls:0.62%
cases:1.46%
controls:0.19%
—
—
—
—
—
—
cases:0.58%
controls:0.28%
cases:4.16%
controls:1.16%
16
55
876
8865
13
17
879
8903
—
—
—
5
24
853
8436
19
54
438
4613
pseudoephedrine; oral
R01BA02 [21603210]
1.3e+00
1.4e+00
1.3e+00
—
—
1.0e+00
7.3e-01
cases:14.91%
controls:4.75%
cases:5.27%
controls:1.37%
cases:0.56%
controls:0.16%
—
—
—
—
cases:4.31%
controls:1.57%
cases:8.53%
controls:4.29%
133
424
759
8496
47
122
845
8798
5
14
887
8906
—
—
37
133
821
8327
39
200
418
4467
Immunization
WW200 [2001310599]
1.5e+00
2.9e+00
—
—
—
—
—
cases:2.80%
controls:0.65%
cases:1.23%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
25
58
867
8862
11
6
881
8914
—
—
—
—
—
Varicella zoster virus Ab [Titer] in Serum
21594-7 [3014148]
3.1e-01
2.1e+00
—
—
—
2.3e+00
—
cases:1.01%
controls:0.74%
cases:1.35%
controls:0.17%
—
—
—
—
—
—
cases:0.93%
controls:0.09%
—
—
9
66
883
8854
12
15
880
8905
—
—
—
8
8
850
8452
—
bilastine; oral
R06AX29 [40256760]
1.9e+00
2.5e+00
—
—
—
—
1.4e+00
cases:3.70%
controls:0.57%
cases:2.35%
controls:0.20%
—
—
—
—
—
—
—
—
cases:1.53%
controls:0.39%
33
51
859
8869
21
18
871
8902
—
—
—
—
7
18
450
4649
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
1.0e+00
2.2e+00
—
—
—
1.1e+00
4.4e-01
cases:7.29%
controls:2.81%
cases:5.16%
controls:0.57%
—
—
—
—
—
—
cases:1.75%
controls:0.58%
cases:3.06%
controls:1.99%
65
251
827
8669
46
51
846
8869
—
—
—
15
49
843
8411
14
93
443
4574
Neutrophils [#/volume] in Blood
26499-4 [3017732]
6.3e-01
1.4e+00
5.1e-01
—
6.6e-01
1.1e+00
1.2e+00
cases:5.16%
controls:2.83%
cases:5.16%
controls:1.36%
cases:0.56%
controls:0.34%
—
—
cases:0.67%
controls:0.35%
cases:6.64%
controls:2.26%
cases:22.32%
controls:7.76%
46
252
846
8668
46
121
846
8799
5
30
887
8890
—
6
31
886
8860
57
191
801
8269
102
362
355
4305
Pruritus, unspecified
L29.9 [45548195]
1.0e+00
2.1e+00
—
—
—
2.3e+00
9.4e-01
cases:0.90%
controls:0.33%
cases:0.78%
controls:0.10%
—
—
—
—
—
—
cases:0.70%
controls:0.07%
cases:1.09%
controls:0.43%
8
29
884
8891
7
9
885
8911
—
—
—
6
6
852
8454
5
20
452
4647
cefalexin; oral
J01DB01 [21602870]
9.0e-01
1.0e+00
1.1e+00
—
7.4e-01
7.3e-01
6.3e-01
cases:51.46%
controls:30.06%
cases:19.96%
controls:8.41%
cases:2.35%
controls:0.83%
—
—
cases:1.91%
controls:0.92%
cases:14.57%
controls:7.61%
cases:34.14%
controls:21.56%
459
2681
433
6239
178
750
714
8170
21
74
871
8846
—
17
82
875
8809
125
644
733
7816
156
1006
301
3661
Drug-induced osteoporosis with pathological fracture
M80.4 [45567669]
2.2e+00
2.2e+00
—
—
—
—
—
cases:0.67%
controls:0.08%
cases:0.67%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
6
7
886
8913
6
7
886
8913
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
719
669
51.26
307.65
3.0
1.3
857.57
224.76
u/ml
7.89
711
623
252
73
47.72
307.65
1.7
1.1
2.09
0.48
u/ml
1.72
191
34
247
238
13.97
235.11
1.3
1.1
4.05
2.07
u/ml
0.95
183
125
219
206
13.77
210.65
1.3
1.1
3.61
5.56
u/ml
0.82
156
116
231
265
11.41
193.37
1.4
1.2
—
—
—
0
0
206
202
12.96
192.14
1.3
1.1
3.57
1.41
u/ml
1.63
155
103
870
4123
46.01
186.62
11.8
6.7
0.60
0.56
e9/l
7.11
831
3588
870
4131
45.84
185.99
11.8
6.7
0.05
0.04
e9/l
7.19
829
3595
199
198
12.65
183.49
1.3
1.1
1.55
0.72
u/ml
0.90
134
83
685
2586
8.11
182.15
9.8
6.8
—
—
—
0
0
877
4269
63.70
180.89
12.6
7.0
0.33
0.19
e9/l
33.97
843
3779
871
4224
46.11
179.53
11.9
6.7
1.99
1.97
e9/l
0.14
835
3767
806
3895
12.09
154.95
11.7
6.7
27.90
28.95
%
2.69
806
3723
172
183
11.41
150.37
1.3
1.0
8.14
3.25
u/ml
2.27
135
95
863
4567
28.36
148.93
12.1
9.8
4.15
3.99
e9/l
1.73
823
4005
162
168
11.56
143.98
1.3
1.1
6.15
6.44
u/ml
0.05
120
72
120
90
15.25
130.39
3.6
2.6
—
—
—
0
0
149
158
11.12
129.96
1.2
1.0
0.69
0.24
u/ml
0.87
98
50
285
811
4.69
93.64
3.0
2.1
279.54
377.98
nmol/l
16.06
277
768
252
676
4.80
88.76
5.3
4.9
0.36
0.66
%
1.32
62
188
249
669
4.78
87.41
5.6
5.2
0.05
0.14
%
0.84
57
168
92
85
11.95
87.36
1.4
1.3
0.31
0.33
g/l
0.22
75
64
92
85
11.95
87.36
1.4
1.3
6.20
6.58
g/l
0.40
75
64
92
85
11.95
87.36
1.4
1.3
2.78
2.92
g/l
0.30
75
63
91
85
11.81
85.77
1.5
1.3
—
—
—
0
0
249
682
4.68
85.12
6.0
5.5
0.02
0.13
%
1.34
53
153
293
912
4.30
84.59
2.5
1.6
—
—
—
0
0
253
705
4.61
84.55
5.6
5.0
0.61
1.01
%
1.08
61
205
239
676
4.46
77.77
2.7
2.7
10.07
10.54
g/l
1.05
227
632
144
274
6.07
74.44
1.7
1.6
0.24
0.24
g/l
0.10
139
263
105
145
8.07
73.47
1.9
1.8
1.30
0.81
g/l
1.91
86
120
73
64
12.33
71.48
1.3
1.5
6.06
6.42
ug/l
0.17
68
54
333
1283
3.55
68.39
1.5
1.4
334.74
496.61
titre
1.64
57
277
148
314
5.45
67.77
1.5
1.3
—
—
—
0
0
277
952
3.77
67.70
2.0
1.5
—
—
—
0
0
443
2055
3.30
66.81
8.2
4.8
—
—
—
0
0
47
21
23.57
64.58
1.2
1.0
1.42
3.42
u/ml
0.30
37
16
621
3607
3.38
62.21
15.8
10.7
0.00
0.00
e9/l
0.94
553
2966
46
24
20.15
59.22
1.1
1.1
2.19
1.12
u/ml
0.60
30
12
278
1037
3.44
58.88
2.7
3.4
4.03
5.44
e9/l
1.53
264
936
187
534
4.17
58.85
1.7
1.8
1.06
1.31
g/l
2.03
173
504
60
64
9.98
51.20
1.2
1.0
7.15
0.54
u/ml
1.10
38
16
47
35
14.12
50.54
1.2
1.1
9.07
15.07
u/ml
—
19
7
252
982
3.18
48.54
2.0
1.4
—
—
—
0
0
55
61
9.54
45.54
1.2
1.0
15.67
0.34
u/ml
0.99
33
23
256
1044
3.04
45.18
2.2
2.1
—
—
—
0
0
52
61
8.99
41.21
1.2
1.0
—
—
—
0
0
363
1893
2.55
38.69
1.8
1.5
2.24
2.29
g/l
0.28
275
1229
40
41
10.17
34.98
1.1
1.0
5.41
14.00
u/ml
1.22
31
32
768
5844
3.26
34.94
8.5
8.1
73.84
77.47
u/l
1.43
753
5582
159
573
3.16
33.99
1.2
1.2
—
—
—
0
0
52
86
6.36
30.47
5.4
2.7
—
—
—
0
0
33
33
10.35
29.30
1.4
1.5
7.83
8.58
ug/l
0.52
33
33
38
12
33.00
29.27
2.1
4.5
—
—
—
0
0
65
138
5.00
29.18
3.5
3.7
4.78
4.24
e9/l
0.91
65
138
42
59
7.42
28.61
1.2
1.0
1.35
0.81
u/ml
—
25
10
117
389
3.31
28.36
1.5
2.0
3.76
6.90
iu/ml
1.13
19
83
71
181
4.18
25.36
3.5
3.5
57.93
56.72
%
0.31
71
181
36
18
20.78
24.48
1.4
1.0
5.02
0.61
u/ml
—
30
10
306
1800
2.07
21.75
3.9
4.2
—
—
—
0
0
879
7833
9.38
21.22
20.8
13.4
15.76
21.81
mg/l
8.92
801
6344
368
2337
1.98
20.91
7.4
6.0
—
—
—
0
0
541
3977
1.92
19.22
5.0
6.6
9.74
10.91
umol/l
2.31
516
3799
29
42
7.10
19.18
1.8
1.7
2752.00
3931.43
titre
—
5
7
304
1869
1.95
18.49
1.9
1.8
0.68
1.05
mg/l
2.86
240
1421
496
3578
1.87
18.32
3.0
2.5
75.98
75.05
nmol/l
0.33
473
3305
38
78
5.04
17.70
1.3
2.6
1673.34
1247.42
e6/l
1.61
29
69
286
1745
1.94
17.64
3.2
2.9
338.97
728.82
ng/l
7.66
239
1424
45
108
4.33
17.37
1.3
1.2
—
—
—
0
0
94
365
2.76
17.14
1.2
1.2
0.25
1.71
u/ml
—
6
18
394
2684
1.84
17.11
3.9
3.2
18.95
57.84
ng/l
0.92
243
1621
214
1202
2.03
16.62
2.6
3.5
0.82
0.82
mmol/l
0.02
202
1155
107
451
2.56
16.56
2.6
3.4
7.42
7.42
ph
0.95
90
374
439
3124
1.80
16.23
3.9
5.0
36.77
36.76
g/l
0.02
419
2966
196
1076
2.05
16.16
1.3
1.2
—
—
—
0
0
330
2161
1.84
16.03
1.5
1.3
1.24
1.62
u/ml
0.28
97
622
24
14
17.58
15.67
1.1
1.0
3.11
0.04
u/ml
—
16
7
163
844
2.14
15.66
1.3
1.5
—
—
—
0
0
144
710
2.23
15.64
1.4
1.2
81.72
145.74
u/ml
2.20
51
292
31
60
5.32
15.41
1.3
2.6
524.71
507.75
e6/l
0.07
21
48
328
2167
1.81
15.33
1.9
2.1
—
—
—
0
0
425
3043
1.76
14.99
9.1
9.4
1.11
1.13
inr
0.46
360
2493
654
5318
1.86
14.75
4.9
4.2
—
3.88
—
0
8
744
6317
2.07
14.70
5.2
4.4
14.76
14.52
pmol/l
2.22
710
5930
303
1978
1.81
14.59
2.6
2.6
334.29
331.63
umol/l
0.19
281
1803
355
2432
1.76
14.47
2.6
2.7
52.44
61.60
u/l
2.44
329
2276
21
12
17.89
13.88
1.1
1.0
0.14
3.12
u/ml
—
13
5
25
44
5.82
13.73
2.0
4.2
408.20
694.43
u/ml
1.54
25
44
468
3506
1.70
13.53
5.9
7.3
1.22
1.21
mmol/l
0.90
400
3061
545
4261
1.72
13.39
3.9
3.5
10.05
3.60
estimate
0.27
150
876
107
496
2.31
13.38
2.1
2.7
67.67
67.59
g/l
0.04
102
472
424
3108
1.69
13.17
2.0
2.0
—
—
—
0
0
29
61
4.88
13.14
1.4
2.7
221.00
215.35
e6/l
0.06
21
52
63
229
2.88
12.97
2.7
2.6
9.52
11.40
mg/l
2.03
63
215
424
3117
1.69
12.96
6.1
6.7
1.22
1.21
mmol/l
0.23
403
2920
539
4227
1.70
12.84
3.9
3.4
0.00
0.00
estimate
0.50
149
867
333
2309
1.71
12.57
3.5
3.1
—
0.83
—
0
6
384
2766
1.68
12.56
4.1
3.6
18.68
78.21
e6/l
2.76
281
1837
542
4289
1.67
12.18
3.9
3.5
0.02
0.01
estimate
0.18
148
815
89
398
2.37
12.07
2.2
2.3
—
—
—
0
0
258
1692
1.74
11.78
1.4
1.3
24.95
28.67
iu/ml
0.21
74
521
203
1242
1.82
11.75
1.4
1.6
—
—
—
0
0
103
496
2.22
11.74
2.7
3.3
77.91
73.72
e9/l
0.42
78
352
46
148
3.22
11.68
3.5
2.9
—
—
—
0
0
15
5
30.47
11.67
2.8
1.6
43.73
35.00
umol/l
—
15
5
244
1579
1.75
11.66
1.4
1.3
8.92
11.94
u/ml
0.33
95
660
547
4384
1.64
11.28
5.1
5.0
6.39
6.51
mmol/l
0.81
528
4109
277
1872
1.70
11.25
2.7
2.1
2.70
2.76
mg/l
0.20
258
1616
239
1558
1.73
11.05
2.7
2.6
7.52
6.72
e6/l
0.20
219
1413
25
54
4.73
11.00
1.1
1.1
1393.68
1497.37
miu/ml
0.19
25
54
410
3076
1.62
10.96
2.1
1.9
98.82
97.48
pmol/l
0.27
262
1638
599
4940
1.65
10.76
4.7
4.1
305.71
688.34
e6/l
—
7
62
892
8660
+∞
10.73
32.9
20.5
90.69
90.53
fl
0.55
892
8593
851
7834
2.88
10.72
19.2
14.7
3.89
3.94
mmol/l
7.47
843
7671
892
8662
+∞
10.53
33.3
20.9
41.86
40.96
%
10.10
892
8588
892
8662
+∞
10.53
32.8
20.4
30.19
30.24
pg
0.40
892
8594
44
147
3.10
10.51
1.3
1.2
—
—
—
0
0
74
324
2.40
10.51
2.7
3.6
—
—
—
0
0
323
2304
1.63
10.49
3.2
3.1
33.44
44.20
e6/l
0.24
252
1707
892
8666
+∞
10.34
33.3
20.6
139.10
137.30
g/l
4.12
892
8596
119
637
2.00
10.25
3.7
3.6
—
—
—
0
0
72
324
2.33
9.62
1.7
1.6
7.44
8.20
u/ml
0.13
15
87
121
667
1.94
9.57
3.0
3.2
1.81
1.82
%
0.01
115
610
306
2194
1.60
9.54
2.0
2.1
200.96
198.57
u/l
0.02
294
2100
314
2270
1.59
9.43
3.8
3.6
0.00
0.01
estimate
1.28
148
835
878
8290
4.77
9.38
15.4
11.2
28.60
27.55
u/l
0.57
873
8119
845
7822
2.52
9.22
19.0
14.6
139.84
139.68
mmol/l
1.39
836
7680
152
914
1.80
9.14
1.4
1.4
—
—
—
0
0
20
27
7.55
8.96
1.2
2.6
0.33
0.29
e9/l
0.12
11
14
37
123
3.10
8.94
4.4
3.6
2.56
2.46
mmol/l
0.08
26
81
437
3441
1.53
8.79
3.3
3.1
6.16
6.19
ph
0.22
264
2026
279
1991
1.58
8.72
2.9
2.9
0.21
0.35
e6/l
1.26
210
1408
506
4126
1.52
8.54
3.9
3.1
89.36
104.45
ug/l
1.09
484
3915
51
207
2.55
8.53
1.6
1.8
9.28
10.47
g/l
0.99
44
197
333
2490
1.54
8.40
2.0
3.3
2.34
2.36
mmol/l
1.19
314
2300
329
2457
1.54
8.33
3.1
2.9
0.00
0.02
estimate
1.74
134
719
188
1232
1.67
8.26
2.8
2.6
110.94
113.76
ug/g
0.06
152
992
804
7351
1.95
8.24
6.4
5.3
1.76
1.80
mu/l
0.57
779
6965
181
1178
1.67
8.15
2.2
2.5
13.75
14.09
umol/l
0.22
171
1103
199
1333
1.63
8.00
2.6
2.7
553.59
536.81
mosm/kgh2o
0.44
177
1168
285
2085
1.54
7.83
3.6
4.1
7.40
7.40
ph
0.70
209
1475
14
13
10.92
7.81
1.4
1.6
—
—
—
0
0
15
16
9.51
7.80
1.1
1.0
0.96
1.20
u/ml
—
10
6
96
530
1.91
7.53
3.0
3.7
1.23
1.23
mmol/l
0.01
87
465
168
1099
1.65
7.37
2.2
2.4
2.53
2.39
g/l
2.67
157
1016
670
5897
1.55
7.20
3.7
3.3
41.30
45.27
u/l
0.84
647
5653
23
65
3.61
7.18
1.1
1.1
101.74
112.86
pmol/l
0.85
23
65
84
457
1.93
6.89
1.1
1.1
—
201.60
—
0
10
407
3268
1.45
6.83
3.6
3.3
0.00
0.02
estimate
2.19
132
733
13
15
8.78
6.56
1.1
1.2
—
—
—
0
0
247
1810
1.50
6.55
1.6
1.7
—
—
—
0
0
120
740
1.72
6.54
1.2
1.2
—
—
—
0
0
37
148
2.56
6.43
1.2
1.2
—
—
—
0
0
260
1936
1.48
6.34
1.7
1.6
19.42
20.59
nmol/l
0.80
230
1671
150
994
1.61
6.19
2.2
2.5
22.96
23.69
%
0.25
138
935
22
67
3.34
6.17
1.2
1.2
—
—
—
0
0
861
8198
2.45
5.96
15.9
11.8
—
—
—
0
0
82
472
1.81
5.66
1.3
1.2
—
—
—
0
0
36
153
2.41
5.54
2.0
2.2
139.56
133.13
g/l
0.86
27
124
782
7266
1.62
5.29
6.4
5.6
38.29
38.31
mmol/mol
0.02
756
6933
28
109
2.62
5.17
1.1
1.3
—
52.11
—
0
7
355
2887
1.38
5.09
3.1
3.4
32.23
31.70
u/l
0.07
340
2744
795
7436
1.64
5.00
4.3
4.0
1.30
1.30
mmol/l
0.09
758
7017
22
77
2.90
4.95
3.2
2.8
32.14
33.18
pg
0.65
22
77
51
263
2.00
4.93
2.8
3.8
191.00
340.95
mg/l
0.96
13
119
28
113
2.53
4.83
1.8
1.7
—
—
—
0
0
28
113
2.53
4.83
1.7
1.7
—
—
—
0
0
28
113
2.53
4.83
1.8
1.7
—
—
—
0
0
28
113
2.53
4.83
1.7
1.7
—
—
—
0
0
828
7839
1.78
4.83
5.2
4.7
4.85
4.75
mmol/l
2.29
795
7460
89
550
1.69
4.82
1.1
1.1
—
—
—
0
0
138
951
1.53
4.78
1.7
1.6
1142.84
1173.43
nmol/l
0.13
113
740
40
192
2.13
4.68
2.1
3.1
1.45
2.50
index
0.69
20
103
110
728
1.58
4.55
6.7
9.4
1.30
0.76
mmol/l
0.98
89
611
109
721
1.58
4.52
2.2
2.1
0.00
0.03
estimate
0.78
22
166
824
7813
1.72
4.47
5.0
4.7
1.51
1.46
mmol/l
2.20
791
7409
187
1392
1.43
4.39
1.8
1.6
42073596.04
35449731.60
pmol/l
0.05
164
1213
110
736
1.56
4.34
6.6
9.3
11.76
12.61
kpa
1.19
104
716
110
736
1.56
4.34
6.6
9.3
4.99
5.13
kpa
0.85
103
714
95
614
1.61
4.34
3.4
4.1
7.39
7.35
ph
2.25
79
450
38
185
2.10
4.31
1.1
1.1
7.37
16.25
au/ml
—
10
62
830
7896
1.74
4.30
5.5
5.2
2.88
2.83
mmol/l
1.11
797
7498
178
1319
1.44
4.28
3.6
3.5
92.85
593.19
ng/l
2.93
112
882
32
146
2.24
4.25
1.8
3.0
6.15
7.90
pmol/l
0.70
32
146
109
734
1.55
4.19
6.8
9.4
7.44
7.42
ph
1.81
56
394
23
91
2.57
4.16
1.2
1.1
30.96
14.99
u/ml
—
9
44
45
239
1.93
4.04
1.7
2.0
0.94
2.13
ug/l
0.50
37
221
99
659
1.56
4.00
6.8
9.9
96.66
96.07
%
1.02
93
644
175
1309
1.42
3.98
1.9
2.6
2.43
2.43
mmol/l
0.13
160
1182
48
264
1.86
3.89
1.2
1.1
—
—
—
0
0
84
542
1.61
3.88
3.3
3.7
4.57
4.68
pmol/l
0.56
75
485
79
505
1.62
3.79
1.8
2.2
7146.65
5862.78
u/l
0.13
23
223
32
156
2.09
3.65
2.1
2.1
3.71
5.21
umol/l
0.88
21
115
64
394
1.67
3.56
2.2
2.2
0.00
1.79
estimate
0.50
18
140
62
380
1.68
3.51
7.5
8.4
24.92
24.57
mmol/l
0.38
57
366
250
2021
1.33
3.47
2.8
2.6
—
—
—
0
0
93
632
1.53
3.45
7.2
10.1
132.41
122.74
g/l
5.42
88
622
13
43
3.05
3.26
1.4
1.6
1.36
1.44
nmol/l
—
7
31
391
3386
1.28
3.17
2.1
1.9
1.38
1.41
mmol/l
0.21
326
2955
783
7433
1.44
3.15
5.1
4.5
5.61
5.82
mmol/l
7.81
747
6981
418
3655
1.27
3.12
3.0
2.9
—
—
—
0
0
122
894
1.42
3.11
2.0
2.9
4.43
6.77
umol/l
3.03
104
786
19
80
2.40
3.07
1.1
1.4
—
—
—
0
0
8
16
5.03
3.05
1.0
1.1
0.10
0.02
u/ml
—
8
16
46
272
1.73
3.00
1.1
1.2
60.00
103.24
titre
—
6
34
42
242
1.77
2.99
1.3
1.3
—
—
—
0
0
23
108
2.16
2.92
1.3
1.3
0.47
0.55
nmol/l
0.95
23
100
9
22
4.12
2.88
1.7
2.1
43.60
42.60
g/l
—
9
22
16
64
2.53
2.88
1.0
1.1
—
—
—
0
0
20
90
2.25
2.81
1.4
1.6
150.30
23.25
ng/l
0.46
20
90
45
270
1.70
2.80
1.2
1.2
—
1135.00
titre
—
0
8
24
118
2.06
2.73
1.8
1.7
—
—
—
0
0
55
353
1.59
2.66
2.5
1.9
38.46
38.94
nmol/l
0.05
55
343
17
75
2.29
2.52
4.1
2.3
1.30
0.95
%
0.51
12
42
297
2548
1.25
2.47
3.7
3.4
8.32
8.19
mmol/l
0.17
262
2210
266
2259
1.25
2.41
4.3
4.2
4.71
10.12
mg/mmol
2.31
170
1407
6
12
5.03
2.40
1.5
2.5
—
—
—
0
0
415
3704
1.23
2.36
2.4
2.7
—
—
estimate
—
0
0
83
598
1.43
2.35
2.4
2.4
7.75
18.74
au/ml
—
8
65
27
147
1.86
2.35
1.2
1.1
—
—
—
0
0
10
34
2.96
2.28
1.0
1.1
—
—
—
0
0
10
34
2.96
2.28
1.0
1.1
—
—
—
0
0
10
34
2.96
2.28
1.0
1.1
—
—
—
0
0
40
250
1.63
2.19
3.8
7.1
0.92
0.88
%
0.23
34
234
259
2215
1.24
2.18
3.7
3.6
29.28
54.54
mg/l
1.76
162
1417
27
154
1.78
2.06
1.1
1.1
1.41
2.12
eliau/ml
—
9
69
16
76
2.13
2.03
2.4
2.2
—
—
—
0
0
6
16
3.77
1.93
1.0
1.0
10.73
6.02
mg/g
—
6
16
18
92
1.98
1.91
1.2
1.2
—
—
nmol/l
—
0
0
57
400
1.45
1.90
1.1
1.1
—
—
—
0
0
8
28
2.87
1.86
1.0
1.3
—
—
—
0
0
42
278
1.54
1.85
3.9
6.6
1.67
1.64
%
0.07
36
262
30
184
1.65
1.80
3.3
3.5
21.59
69.44
mg/l
0.84
23
155
30
184
1.65
1.80
3.2
3.5
22.29
31.52
mg/l
1.85
23
154
56
396
1.44
1.80
3.4
2.8
82.76
115.92
ng/l
0.47
49
356
8
29
2.77
1.79
1.1
2.2
22.00
30.07
%
—
8
29
13
60
2.18
1.78
1.2
1.1
—
—
—
0
0
98
763
1.32
1.77
3.2
2.4
13.34
13.46
nmol/l
0.05
91
715
15
74
2.04
1.75
1.1
1.2
—
—
—
0
0
16
81
1.99
1.75
1.1
1.2
—
—
—
0
0
18
96
1.89
1.71
1.3
1.2
0.16
0.17
nmol/l
0.43
12
69
15
75
2.02
1.70
1.1
1.1
—
—
—
0
0
27
165
1.66
1.66
3.0
3.3
0.98
1.53
ratio
1.94
13
92
12
56
2.16
1.61
1.1
1.3
—
—
—
0
0
67
500
1.37
1.61
2.3
2.0
—
—
—
0
0
72
544
1.35
1.60
2.4
2.0
—
—
—
0
0
77
588
1.34
1.60
7.2
9.3
—
—
—
0
0
72
545
1.35
1.59
2.2
1.9
—
—
—
0
0
10
43
2.34
1.59
1.2
1.3
145.20
154.88
nmol/l
—
10
43
48
340
1.44
1.56
2.8
1.8
—
—
—
0
0
72
548
1.34
1.54
2.3
1.9
—
—
—
0
0
136
1126
1.25
1.53
2.9
2.7
3.38
2.78
e6/l
0.35
56
503
34
226
1.52
1.51
1.1
1.2
—
—
—
0
0
80
623
1.31
1.47
2.3
2.0
6.19
6.13
ph
0.20
42
395
17
291
0.58
1.46
1.5
1.5
1.08
1.26
mm
1.33
11
207
21
125
1.70
1.44
5.2
11.1
103.88
105.38
mmol/l
0.70
16
116
21
125
1.70
1.44
5.2
11.1
10.50
11.35
mmol/l
1.03
16
116
6
22
2.74
1.43
1.0
1.9
—
—
—
0
0
25
385
0.64
1.41
1.6
1.5
46.05
62.91
ug/l
1.66
19
323
36
248
1.47
1.37
1.3
2.0
1.72
1.47
g/l
0.70
28
220
35
240
1.48
1.36
1.5
1.5
330.50
290.92
ug/g
0.47
20
146
112
923
1.24
1.33
7.3
7.7
104.73
104.37
mmol/l
0.40
112
923
6
134
0.44
1.28
2.3
2.6
—
27.19
—
0
11
12
62
1.95
1.28
1.7
2.2
7.80
33.74
mg/l
—
5
46
11
55
2.01
1.27
1.4
1.3
163.89
172.87
pmol/l
0.10
11
55
50
372
1.36
1.27
1.3
1.2
—
—
—
0
0
152
1302
1.20
1.25
1.8
1.8
—
—
—
0
0
8
37
2.17
1.21
1.3
1.2
132.88
182.59
mmol/24h
—
8
37
19
299
0.63
1.21
1.5
1.5
—
—
—
0
0
30
206
1.47
1.19
1.9
2.2
—
—
—
0
0
6
26
2.32
1.19
1.3
1.3
24.67
27.46
s
—
6
26
32
225
1.44
1.13
1.2
1.1
—
—
—
0
0
32
225
1.44
1.13
1.2
1.1
—
—
—
0
0
20
305
0.65
1.12
1.5
1.5
—
—
—
0
0
16
96
1.68
1.10
1.3
1.1
—
—
—
0
0
18
112
1.62
1.09
2.2
2.3
—
—
—
0
0
275
2504
1.14
1.05
2.1
2.3
—
—
—
0
0
6
125
0.48
1.05
1.2
1.3
—
—
—
0
0
68
546
1.27
1.04
2.4
1.9
—
—
—
0
0
73
592
1.25
1.03
1.2
1.3
25.01
25.24
iu/l
0.02
66
512
32
230
1.41
1.03
3.2
2.5
—
—
—
0
0
54
423
1.29
1.01
1.4
1.3
171.49
236.27
miu/ml
0.59
18
213
7
36
1.95
0.97
1.6
4.0
7.80
8.70
mmol/l
—
7
36
26
182
1.44
0.97
1.3
1.6
7446.68
11414.51
e6/l
0.39
19
136
23
157
1.48
0.97
1.2
1.2
6.13
5.34
u/ml
0.09
15
67
140
1222
1.17
0.95
2.8
2.6
0.64
0.96
e6/l
0.97
62
600
150
1317
1.17
0.95
1.6
1.5
—
—
—
0
0
6
27
2.23
0.93
2.3
1.4
—
—
—
0
0
116
1000
1.18
0.92
1.3
1.2
—
—
—
0
0
10
170
0.58
0.90
1.1
1.5
3.38
2.78
ug/l
—
10
154
132
1153
1.17
0.90
3.1
2.7
0.55
0.67
ug/l
2.29
71
628
34
254
1.35
0.89
2.4
2.0
3.22
4.11
iu/l
0.31
13
105
23
160
1.45
0.89
1.1
1.1
—
—
—
0
0
6
30
2.01
0.87
1.7
4.5
17.55
17.00
%
—
6
30
53
656
0.80
0.86
1.5
1.6
880.61
998.22
mu/l
0.52
45
550
10
167
0.59
0.85
1.7
1.6
—
—
—
0
0
80
675
1.20
0.82
3.7
4.1
7.40
7.38
ph
1.38
29
390
24
173
1.40
0.79
1.0
1.1
—
—
—
0
0
14
90
1.56
0.78
1.0
1.1
—
—
—
0
0
5
24
2.09
0.74
1.0
1.0
49.18
36.48
iu/ml
—
5
24
49
598
0.81
0.73
1.8
1.7
—
—
—
0
0
29
221
1.32
0.70
1.1
1.2
203.94
244.81
u/ml
0.61
16
131
118
1045
1.15
0.70
1.6
1.8
—
—
—
0
0
12
77
1.57
0.68
1.8
6.0
11.64
11.17
%
0.15
12
77
201
1844
1.12
0.68
4.8
4.3
1.51
1.92
ug/l
1.11
186
1700
15
215
0.69
0.68
1.1
1.3
—
—
—
0
0
75
644
1.18
0.66
3.4
4.0
1.63
1.82
mmol/l
0.14
70
557
10
62
1.62
0.65
1.0
1.6
—
—
—
0
0
10
62
1.62
0.65
1.0
1.1
—
—
—
0
0
34
269
1.27
0.64
1.9
4.0
1.19
1.37
mg/l
1.27
34
250
38
305
1.26
0.64
2.1
1.7
—
—
—
0
0
60
507
1.20
0.64
3.0
4.0
76.76
80.03
ng/l
0.11
52
458
85
745
1.16
0.60
2.5
2.6
47.67
107.32
u/l
0.44
69
633
26
202
1.30
0.58
1.2
1.5
2.60
9.24
e6/l
1.11
20
152
8
54
1.49
0.57
1.4
2.7
—
—
—
0
0
18
132
1.37
0.57
1.3
1.3
—
—
—
0
0
9
60
1.51
0.54
1.1
1.4
87.78
74.40
umol/l
—
9
60
14
99
1.42
0.54
2.5
2.2
—
—
—
0
0
6
39
1.54
0.53
1.7
1.4
—
—
—
0
0
6
39
1.54
0.53
1.5
1.2
105.00
589.97
u/l
—
6
34
6
40
1.50
0.51
1.7
1.7
—
—
—
0
0
201
1876
1.09
0.50
3.6
3.4
1.02
1.02
kg/l
0.02
138
1228
54
625
0.86
0.50
3.2
4.5
2.71
13.57
ug/l
0.92
43
504
33
271
1.23
0.49
1.4
1.2
—
—
—
0
0
7
45
1.56
0.49
1.0
1.1
153.70
155.66
iu/ml
—
7
45
7
46
1.53
0.48
2.3
4.6
1.00
0.85
index
—
7
46
42
358
1.18
0.44
1.5
1.4
12.00
9.01
u/l
0.47
35
293
69
612
1.14
0.44
1.4
1.4
—
—
—
0
0
18
139
1.30
0.44
5.7
3.6
19.27
23.81
mg/l
0.41
11
92
5
32
1.57
0.42
1.4
1.9
57.20
125.47
ng/l
—
5
32
38
442
0.85
0.39
1.4
2.7
20.31
64.91
u/ml
1.02
38
428
5
35
1.43
0.39
2.6
1.2
0.00
0.09
estimate
—
5
35
5
35
1.43
0.39
3.0
1.6
—
—
—
0
0
5
36
1.39
0.38
1.0
1.3
—
—
—
0
0
9
68
1.33
0.37
2.7
2.6
—
—
—
0
0
6
45
1.34
0.33
1.5
1.4
—
—
—
0
0
7
56
1.25
0.29
1.6
1.2
—
—
—
0
0
18
148
1.22
0.29
1.1
1.1
40.00
59.19
iu/ml
—
5
35
7
57
1.23
0.29
1.1
1.1
1.08
1.05
ratio
—
7
49
52
470
1.11
0.28
1.3
1.7
0.28
0.33
mg/l
0.27
22
226
5
72
0.69
0.26
2.6
2.4
1.20
1.19
mmol/l
—
5
72
5
72
0.69
0.26
2.6
2.4
3.90
4.01
mmol/l
—
5
72
5
72
0.69
0.26
2.6
2.4
109.20
105.28
mmol/l
—
5
72
24
208
1.16
0.24
1.2
1.4
—
—
—
0
0
103
1091
0.94
0.23
1.3
1.3
—
—
—
0
0
5
40
1.25
0.22
1.8
2.0
—
74.12
—
0
6
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
1.61
—
0
13
6
48
1.25
0.20
3.0
1.6
0.63
0.48
e9/l
—
6
48
21
239
0.88
0.19
14.2
8.0
—
—
—
0
0
41
447
0.91
0.19
1.1
1.1
1.51
1.52
g/l
0.08
41
447
6
52
1.15
0.19
1.7
1.4
36.02
34.00
g/l
—
6
47
95
907
1.05
0.16
1.7
1.7
3.75
3.51
mmol/l
1.31
64
652
34
313
1.09
0.15
2.6
2.2
—
—
—
0
0
43
458
0.94
0.13
1.1
1.2
0.89
0.90
g/l
0.10
43
458
11
94
1.17
0.13
1.0
1.8
—
—
—
0
0
16
143
1.12
0.11
1.1
1.2
—
—
—
0
0
16
177
0.90
0.10
2.2
1.8
—
—
—
0
0
11
96
1.15
0.10
1.2
1.7
—
—
—
0
0
21
194
1.08
0.09
1.2
1.4
172.33
162.62
au/ml
—
6
57
7
66
1.06
0.08
1.1
1.1
—
—
—
0
0
20
187
1.07
0.06
1.1
1.6
—
—
—
0
0
255
2578
0.98
0.06
1.6
1.6
—
—
—
0
0
15
162
0.92
0.06
1.7
2.4
7.60
154.38
ug/min
—
9
92
15
141
1.06
0.03
3.9
3.6
—
—
—
0
0
21
201
1.05
0.03
1.8
1.4
0.48
0.34
nmol/l
0.24
11
165
10
97
1.03
0.00
1.1
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
8.23
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
325.43
—
0
7
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
520.20
—
0
6
0
6
0.00
-0.00
0.0
2.3
—
360.17
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
57.46
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
120
1200
1.00
-0.00
2.1
1.9
3.69
3.51
ratio
0.80
86
939
0
6
0.00
-0.00
0.0
1.0
—
401.67
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
54
0.93
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
15.88
—
0
8
0
9
0.00
-0.00
0.0
4.7
—
7.06
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint RX_ASTMA_BIOL and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have RX_ASTMA_BIOL.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: RX_ASTMA_BIOL – Biological medicines for asthma

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data